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1 
Abstract  
Chlamydia represents a group of Gram-negative bacteria which can infect and cause 
disease in a diverse range of organisms. The most well-known member of the family is 
Chlamydia trachomatis, the most common bacterial sexually transmitted infection across 
the world, which is associated with reproductive complications including infertility and 
miscarriage. In addition, other emerging Chlamydia-like organisms such as Waddlia 
chondrophila are proposed to represent a health threat, as their association with several 
human diseases is being investigated. As human vaccines for these infections are not 
currently available and antibiotic resistance may potentially risk the current treatments 
over the coming years, the discovery of new effective antimicrobial drugs is essential. 
Cationic Host Defence Peptides (CHDPs) are known for their key role in the innate 
immune response. In mammals, there are two main families of CHDPs, cathelicidins and 
defensins. These peptides have been identified in several different cell types including 
epithelial cells, macrophages and neutrophils among others. The human cathelicidin, LL-
37, displays broad spectrum antimicrobial and immunomodulatory potential following 
proteolytic cleavage from the precursor molecule hCAP-18. In addition to their direct 
antimicrobial activity, cathelicidins have been shown to influence the inflammatory 
response to pathogens and to play a role in wound repair and immune cell recruitment 
and differentiation. As such, they represent exciting prospects for the development of 
novel peptide-based therapeutics for a range of infections. 
This study investigated the activity of cathelicidins from humans and animals against 
different Chlamydia and Waddlia chondrophila, assessing changes in bacterial 
population as well as immunomodulatory effects on the epithelial host cell line, HEp2, 
during infection. Our results show that cathelicidins can have a direct effect on Chlamydia 
populations and that the effect is most visible when the pathogen is directly exposed to 
the peptide. We demonstrate that cathelicidins can directly modulate the host cell 
response to these infections, likely through direct inhibition of the pathogen induced 
inflammatory response, rather than by modulation of host cell death pathways. 
Furthermore, we demonstrate that the emerging pathogen Waddlia chondrophila appears 
to show intrinsic resistance to the activity of these peptides, potentially representing a 
concerning trait of this organism in terms of innate immune evasion. 
	  
2 
Acknowledgements 
To my parents, for making it possible for me to study this Master. You have always been 
there for me and seen the potential I have in me. I owe you the world.  
 
To Dr Peter Barlow and Dr Nick Wheelhouse for all their help and supervision during 
this year. Thanks to all your support you made me feel ready to pursue the next step in 
my research career. 
 
To my friends Victor, Filipa, Olga, Kirsty and Sophie. You have made me feel at home 
since the first day and have endured all my questions. Thanks to you I have enjoyed the 
most of this year and learned how I would like to be in the future. 
 
I would like to acknowledge all the technical staff that have helped me during this year 
as well as Edinburgh Napier University for funding the fees studentship for this project. 
  
	  
3 
TABLE OF CONTENTS 
Abstract ............................................................................................................................. 1 
Acknowledgements ........................................................................................................... 2 
Commonly used abbreviations ......................................................................................... 6 
1. Introduction ............................................................................................................. 9 
1.1 Chlamydiae .................................................................................................................. 9 
1.1.1 Life cycle ...................................................................................................................... 9 
1.1.2 Chlamydia trachomatis ............................................................................................. 12 
1.1.3 Waddlia chondrophila ............................................................................................... 21 
1.2 Antimicrobial resistance ............................................................................................ 25 
1.2.1 Antibiotic resistance in Chlamydia species .............................................................. 25 
1.3 Cationic Host Defence Peptides ................................................................................ 26 
1.3.1 Defensins .................................................................................................................... 27 
1.3.2 Cathelicidins .............................................................................................................. 27 
1.4 Hypothesis .................................................................................................................. 34 
1.5 Research Aims ........................................................................................................... 34 
1.6 Research Objectives ................................................................................................... 35 
2 Materials and methods ........................................................................................... 36 
2.1 Cell culture ................................................................................................................. 36 
2.2 Cathelicidins .............................................................................................................. 36 
2.3 Chlamydia trachomatis and Waddlia chondrophila propagation ........................... 37 
2.4 Determination of bacterial titer ................................................................................. 37 
2.5 Direct cathelicidin treatment of C. trachomatis and W. chondrophila ................... 38 
2.6 Host cell exposure to cathelicidins prior infection ................................................... 38 
2.7 DNA extraction .......................................................................................................... 39 
2.8 Real-Time PCR .......................................................................................................... 39 
2.9 Immunostaining of bacterial inclusions ................................................................... 40 
2.10 Lactate Dehydrogenase assay ................................................................................... 40 
2.11 IL-8 Enzyme Linked ImmunoSorbent Assay (ELISA) ............................................ 41 
3 Results .................................................................................................................... 43 
3.1 The direct antimicrobial effects of cathelicidins on C. trachomatis and W. 
chondrophila .......................................................................................................................... 43 
3.1.1 Exposure to LL-37, PG-1 or SMAP-29 reduces Chlamydia trachomatis infectivity
 43 
3.1.2 Exposure to LL-37, PG-1 and SMAP-29 reduces Chlamydia trachomatis replication
 46 
	  
4 
3.1.3 Exposure to LL-37, PG-1 or SMAP-29 increases Waddlia chondrophila infectivity
 48 
3.1.4 Exposure to LL-37, PG-1 or SMAP-29 increases W. chondrophila replication ..... 49 
3.2 The effect of host cell exposure to cathelicidins on C. trachomatis and W. 
chondrophila infection .......................................................................................................... 52 
3.2.1 Host cell exposure to LL-37, but not PG-1 or SMAP-29, alters subsequent C. 
trachomatis infectivity ....................................................................................................... 52 
3.2.2 Host cell exposure to LL-37, PG-1 or SMAP-29 does not alter C. trachomatis 
replication ........................................................................................................................... 53 
3.2.3 Host cell exposure to LL-37, PG-1 or SMAP-29 does not alter W. chondrophila 
infectivity ............................................................................................................................. 55 
3.2.4 Host cell exposure to LL-37, PG-1 or SMAP-29 does not alter W. chondrophila 
replication ........................................................................................................................... 57 
3.3 The effect of cathelicidin exposure on host cell death ............................................. 59 
3.3.1 Exposure to LL-37, PG-1 and SMAP-29 does not induce necrosis in C. trachomatis 
infected host cells ............................................................................................................... 59 
3.3.2 Exposure to LL-37, PG-1 and SMAP-29 does not induce necrosis in W. 
chondrophila infected host cells ........................................................................................ 61 
3.4 The effect of cathelicidins on the host inflammatory response during C. 
trachomatis and W. chondrophila infection ......................................................................... 63 
3.4.1 Modulation of IL-8 release by cathelicidins in uninfected host cells ...................... 63 
3.4.1.1 Exposure to LL-37, PG-1 and SMAP-29 does not alter IL-8 release by HEp2 
cells………………………………………………………………………………………...6
3 
3.4.2 The effect of cathelicidins on IL-8 production in C. trachomatis infection ........... 65 
3.4.2.1 Cathelicidins dramatically enhance IL-8 release by host cells during C. 
trachomatis infection .......................................................................................................... 65 
3.4.2.2 Host cell exposure to LL-37, PG-1 and SMAP-29 prior to C. trachomatis 
infection can alter IL-8 release .......................................................................................... 67 
3.4.3 The effect of cathelicidins on IL-8 production in W. chondrophila infection ........ 70 
3.4.3.1 LL-37, PG-1 and SMAP-29 exposure alters W. chondrophila induced IL-8 
production in epithelial host cells ...................................................................................... 70 
3.4.3.2 Host cell exposure to LL-37, PG-1 and SMAP-29 prior to W. chondrophila 
infection does not alter IL-8 production ............................................................................ 72 
3.5 Intracellular localisation of Dansyl-labelled LL-37 ................................................ 74 
3.5.1 dLL-37 can enter the host cell ................................................................................... 74 
3.5.2 Dansyl-LL-37 co-localizes with the intracellular bacterial inclusions .................... 76 
4 Discussion .............................................................................................................. 78 
4.1 The direct antimicrobial effects of cathelicidins on C. trachomatis and W. 
chondrophila .......................................................................................................................... 78 
4.1.1 Exposure of Chlamydia trachomatis to LL-37, PG-1 or SMAP-29 prior to host cell 
infection reduces replication and infectivity ..................................................................... 79 
4.1.2 Exposure of W. chondrophila to LL-37, PG-1 or SMAP-29 increases replication and 
infectivity ............................................................................................................................. 80 
	  
5 
4.2 The effect of host cell exposure to cathelicidins on C. trachomatis and W. 
chondrophila infection .......................................................................................................... 82 
4.2.1 Host cell exposure to LL-37, but not PG-1 or SMAP-29, alters subsequent C. 
trachomatis replication ...................................................................................................... 82 
4.2.2 Host cell exposure to LL-37, PG-1 or SMAP-29 does not alter W. chondrophila 
replication and infectivity ................................................................................................... 83 
4.3 The effect of cathelicidins exposure on host cell death ........................................... 84 
4.4 The effect of cathelicidins on the host cell inflammatory response during C. 
trachomatis and W. chondrophila infection ......................................................................... 86 
4.4.1 Cathelicidins enhance IL-8 release by host cells during C. trachomatis infection 87 
4.4.2 Host cell IL-8 production is only altered after W. chondrophila exposure to LL-37, 
PG-1 and SMAP-29 ............................................................................................................ 88 
4.5 Intracellular localisation of Dansyl-labelled LL-37 ................................................ 90 
4.6 Final conclusions and future work ........................................................................... 91 
5 Results appendix .................................................................................................... 93 
6 References .............................................................................................................. 96 
 
  
	  
6 
Commonly used abbreviations 
CHDP – Cationic Host Defence Peptide 
HDP – Host Defence Peptide 
hCAP18 – Human cationic antimicrobial protein 18 
PRR – Pattern recognition receptor 
TLR – Toll-like receptor 
MIP – Macrophage infectivity potentiator 
HSP60 – Heat shock protein 60 
LPS – Lipopolysaccharide  
MOMP – Major outer membrane porin protein 
T3SS – Type III secretion system 
EB – Elementary body 
RB – Reticulate body 
LGV – Lymphogranuloma venereum 
L2 – LGV II serovar 
PAMP – Pathogen associated molecular pattern  
MyD88 – Myeloid differentiation primary response protein 88 
TNF-a – Tumour necrosis factor alpha 
TRAF-6 – TNF receptor associated factor 6 
NLR – NOD-like receptors 
NOD – Nucleotide-binding olimerization domain 
IL – Interleukin 
PG – Protegrin 
SMAP – Sheep myeloid antimicrobial peptide 
BMAP – Bovine myeloid antimicrobial peptide 
	  
7 
PBS – Phosphate buffer saline 
IMDM – Iscove’s modified Dulbecco’s media 
FBS – Foetal bovine serum  
sLL-37 – Scrambled LL-37 
HEp2 – Human epithelial cells 2 
MOI – Multiplicity of infection 
BSA – Bovine serum albumin 
TRITC – Tetramethylrhodamine 
GFP – Green fluorescent protein  
DAPI – 4′,6-diamidino-2-phenylindole 
LDH – Lactose dehydrogenase  
µM – Micromolar 
µl – Microlitre 
ml – Millilitre 
µg – Microgram 
 
  
	  
8 
 
 
   
	  
9 
1.   Introduction 
 
1.1  Chlamydiae 
Chlamydiae are Gram-negative, obligate intracellular pathogens of diverse host 
organisms, including humans (Bachmann, Polkinghorne and Timms, 2014). Chlamydiae 
are the agents of the most common bacterial sexually transmitted disease as well as other 
infections, such as pneumonia, psittacosis, trachoma, and lymphogranuloma venereum. 
They lack the ability to produce sufficient energy to grow independently, and therefore 
can only complete their life cycle inside a host cell. The best-studied group of the 
Chlamydiae phylum is the Chlamydiaceae family, which comprises 11 species that are 
pathogenic to humans or animals, such as Chlamydia trachomatis and Chlamydia 
pneumoniae (Stephens et al., 1999). 
 
 
1.1.1   Life cycle 
1.1.1.1  Chlamydiae recognition and internalization 
Infection starts when the infectious elementary body attaches to the epithelial host cell 
membrane by the formation of a trimolecular bridge between the bacterial adhesins, the 
host heparan sulphate (like glycosaminoglycan, GAG) and host receptors (Mehlitz and 
Rudel, 2013). This binding is thought to be a two-step process for some species, involving 
an initial reversible interaction with host heparan sulphate-like glycosaminoglycans, 
followed by the high affinity irreversible binding to host cell receptors (Dautry-Varsat, 
Subtil and Hackstadt, 2005). Bacterial adhesins are recognised by pattern recognition 
receptors (PRR), including Toll-like receptors (TLRs). Some chlamydial components 
have been found to be implicated in TLR-dependent cell activation: the lipoprotein 
macrophage infectivity potentiator (MIP), lipopolysaccharide (LPS) and the chlamydial 
heat shock protein (HSP60). Other ligands that have been also found to activate TLR 
signalling pathways in Chlamydia, are chlamydial major outer membrane porin proteins 
(MOMP). Other examples of receptors implicated in the recognition of chlamydial 
PAMPs are mannose-receptors, Epidermal Growth Factor Receptor (EGFR) and estrogen 
receptor complex. When the bacteria have attached to the host cell membrane, pre-
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synthesized type III secretion system (T3SS) effectors are injected in the host cell, which 
allows for cytoskeletal rearrangement to facilitate the bacterial internalisation and the 
establishment of an anti-apoptotic state in the host cell. Of note, Chlamydiae are able to 
induce small GTPase-dependent reorganization of the actin cytoskeleton to promote 
bacterial entry (Dautry-Varsat, Subtil and Hackstadt, 2005; Kumar and Valdivia, 2008). 
The pathogen is then internalised in a membrane-bound vesicle, known as the inclusion. 
 
 
1.1.1.2  Establishment of the inclusion and multiplication 
Bacteria in the phylum Chlamydiae are characterised by their complex intracellular 
developmental cycles. All species belonging to this phylum share a biphasic life cycle in 
which they alternate between an infectious elementary body (EB) and the intracellular 
non-infectious reticulate body (RB) (Figure 1). Once the elementary body has entered the 
host cell in the vesicle-like compartment, early chlamydial gene expression will result in 
avoidance of the natural endolysosomal pathway and in transportation through the 
microtubules network to the microtubule organizing center (MTOC) (Scidmore, 2011). 
Inside the inclusion, the elementary body transits to the reticulate body and bacterial 
protein synthesis is initiated. To ensure essential host lipid and protein acquisition by the 
bacterial inclusion, newly secreted inclusion membrane proteins promote the redirection 
of host membrane trafficking vesicles into the inclusion. The reticulate body then 
replicates exponentially and continues producing more effectors to modulate host cell 
processes. Under in vitro stress conditions, chlamydial inclusions from species of the 
Chlamydiaceae family can enter in a persistent state called aberrant body. In this state, 
replication and mRNA synthesis continue, as well as an aberrant enlargement of the RBs. 
Therefore, cell division is altered, and is not resumed until the stress has been removed 
(Wyrick, 2010). While the molecular mechanism by which Chlamydia enters and exits 
persistence is not known, growing evidence supports the observation that this stage also 
occurs in vivo (Hogan et al., 2004; Schoborg, 2011). The late stages of the infection also 
involve the transition from reticulate bodies to elementary bodies, after 48-72 hours post-
infection, and the elementary bodies then exit the host cell. 
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1.1.1.3  Mechanisms of host cell exit 
Chlamydiae exit occurs by two exclusive pathways: lysis of the inclusion and host cell 
membrane and a packaged release process, called extrusion (Hybiske and Stephens, 
2007). Both pathways take place at similar frequencies. In the case of the first mechanism, 
the spontaneous rupture of the inclusion membrane is followed by the progressive 
permeabilisation of intracellular compartments, ending with the permeabilisation of the 
host cell plasma membrane. These permeabilisations are mostly caused by the activity of 
cell and bacterial proteases (Hybiske and Stephens, 2007). The second exit pathway, 
extrusion, consists in the release of the new elementary bodies inside a membrane 
compartment, leaving the host cell intact. This mechanism of dissemination allows the 
Chlamydia to go undetected from local immune responses, preventing the release of 
inflammatory contents from the host cell. 
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Figure 1. The life cycle of Chlamydia trachomatis. (Elwell, Mirrashidi and Engel, 2016). 
Elementary bodies bind to the host cell by the formation of a trimolecular bridge between bacterial 
adhesins, host receptors and host heparan sulfate proteoglycans (HSPGs). Pre-synthesized type 
III secretion system (T3SS) effectors are then injected into the host cell to facilitate chlamydial 
entry and to promote the establishment of an anti-apoptotic state. The elementary body is 
internalised into a membrane-bound compartment, the inclusion, which rapidly dissociates from 
the canonical endocytic pathway. Next, elementary bodies convert to reticulate bodies and newly 
secreted inclusion membrane proteins (Incs) promote nutrient acquisition by redirecting host cell 
exocytic vesicles from the Golgi apparatus. During the late stages of infection, reticulate bodies 
differentiate back to elementary bodies. Finally, elementary bodies will exit the host through 
extrusion or lysis. 
 
 
1.1.2  Chlamydia trachomatis 
Chlamydia trachomatis is the causative agent of several acute and chronic, as well as 
local and systemic, human diseases such as trachoma, urogenital and neonatal infections. 
C. trachomatis was first identified in 1907 by Halberstaedter and von Prowazec from 
conjunctival scrapings from subjects with trachoma. C. trachomatis was initially thought 
to be protozoa and later a virus, before being correctly identified as intracellular bacteria. 
Because chlamydial infection was first identified in the eye and due to its broad range of 
symptoms, or lack of them, the infection was not thought to be sexually transmitted until 
1976 (Schachter, Causse and Tarizzo, 1976). C. trachomatis strains are divided into three 
biovars, variants that possess physiological and/or biochemical differences from other 
strains, and further subdivided into serovars, which are subdivisions of subspecies 
characterized by a differential set of antigens. The trachoma biovar comprises the 
serovars A-C and is the leading cause of non-congenital blindness in Western countries, 
whereas the genital tract biovar (serovars D-K) is the most common bacterial sexually 
transmitted infection worldwide. Serovars L1-L3 belong to the lymphogranuloma 
venereum (LGV) biovar and cause invasive urogenital and anorectal infection.  
 
 
1.1.2.1  Clinical manifestations 
The various C. trachomatis serovars are responsible of a variety of clinical conditions in 
humans. The trachoma biovar is the leading cause of infectious blindness worldwide 
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(Resnikoff et al., 2008). Although the genital serovars of C. trachomatis can infect the 
ocular tissues, it is unlikely that it will lead to blinding sequelae. Regarding the ocular 
manifestations caused by the trachoma biovar, patients with repeated conjunctival 
infections suffer from chronic inflammation of the conjunctiva and follicle formation on 
its surface. The increasing roughness of the conjunctiva and its scarring, leads to cornea 
scarring which can result in blindness if the infection continues untreated. The clinical 
manifestations of trachoma change with age, being more active at young ages. 
 
Lymphogranuloma venereum (LGV) is a sexually transmitted disease that primarily 
attacks lymphatic and subepithelial tissues of the genital tract, causing primary lesions. 
The early stage of the infection involves painless genital papulae and pustules and is 
normally asymptomatic. Infection of the lymphatic tissue induces a lymphoproliferative 
reaction (Ceovic and Gulin, 2015). LGV infection travels by lymphatics to the lymph 
nodes, where it can infect macrophages and results in systemic disease in the last stage of 
the infection. LGV disease is caused predominantly by the serovar L2. 
 
Urogenital infections caused by C. trachomatis normally affect the urethra and cervix in 
women and urethra in men. C. trachomatis urogenital infection can go undiagnosed as it 
displays higher percentages of asymptomatic infections: 50 per cent of the infected men 
are asymptomatic, whereas in women this percentage is even higher, approximately 70-
80 per cent (Malhotra et al., 2013). Asymptomatic infections can remain undetected, 
which can lead to major complications and a delayed treatment. Untreated infections in 
females can cause pelvic inflammatory disease (Paavonen and Eggert-Kruse, 1999) that 
can lead to infertility (Haggerty et al., 2010) and ectopic pregnancy (Menon et al., 2015). 
C. trachomatis role in miscarriage has been proposed, though the possible link and 
mechanism is still poorly understood (Giakoumelou et al., 2016). 
 
 
1.1.2.2  Host innate immune response 
Chlamydia is recognized in epithelial cells by cell surface receptors, endosomal receptors 
and cytosolic innate immune receptors (Elwell, Mirrashidi and Engel, 2016). These 
receptors recognize conserved pathogen-associated molecular patterns found in certain 
microorganisms and are expressed not only in epithelial but also in dendritic cells and 
	  
14 
innate immune cells, such as macrophages and neutrophils. Chlamydial pathogen-
associated molecular patterns (PAMPs) recognition is highly complex. On binding, the 
pathogen activates the PRRs (predominantly Toll-like receptors). TLRs recognize 
microbial infection and have an essential role in the induction of innate and adaptive 
immune responses. TLR4 recognizes bacterial lipopolysaccharide (LPS), whereas TLR2 
detects bacterial lipoproteins and glycolipids. The implications of more than one Toll-
like receptor were studied using knock-out mice for TLR4 and TLR2 in Chlamydia 
muridarum infection (Entrican et al., 2004; Imtiaz et al., 2006). Chlamydial infection is 
recognized predominantly by TLR2 (Wang et al., 2017). Among the reported molecules 
responsible of innate immune response activation via TLR in Chlamydia are MIP 
(macrophage infectivity potentiator), which is recognized via TLR2/TLR1/TLR6, and 
CD14 and cHSP60 (Heat Shock Protein 60), recognized both via TLR4 and TLR2. Other 
ligands activating TLR2 signaling pathway in Chlamydia infection are chlamydial major 
outer membrane porin proteins (MOMP), TLR1 playing a co-receptor role in its 
recognition (Massari et al., 2013). TLR activation leads to the induction of the innate 
immune response and to pro-inflammatory cytokine production due to a signaling cascade 
that involves the myeloid differentiation primary response protein 88 (MyD88) and 
tumour necrosis factor alpha (TNF-a) receptor associated factor 6 (TRAF-6) (Figure 2). 
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Figure 2. TLR2 and TLR4 dependent inflammatory responses during chlamydial infection. 
Chlamydial PAMPs recognition leads to an activation of the TLR signaling pathway which 
originates from the cytoplasmic Toll/IL-1 receptor (TIR) domain that associates with a TIR 
domain-containing adaptor, MyD88. This association promotes the autophosphorylation of IL-1 
receptor associate kinase (IRAK) by binding to MyD88. Activated IRAK will activate TRAF-6, 
which will stimulate the IΚβ kinase complex (IKK). Activation and phosphorylation of IKK and 
its degradation leads to a translocation of NF-Κβ to the nucleus, promoting the expression of pro-
inflammatory cytokines. 
 
 
Intracellular nucleotide sensors play a role in innate response to Chlamydia as they induce 
the expression of type I interferons and other pro-inflammatory cytokines (Figure 3). 
Recent advances have focused upon the role of the receptors nucleotide-binding 
oligomerisation domain-containing 1 and 2 (NOD1 and NOD2) in chlamydial infection. 
NOD-like receptors (NLRs) participate in the initiation of innate responses against 
intracellular pathogens, recognizing common structural molecules of bacterial walls (e.g. 
peptidoglycan), and promote autophagy in infected cells (Travassos et al., 2010). NOD1 
is ubiquitous to most cell types of hematopoietic and non-hematopoietic origin, whereas 
NOD2 is mainly expressed by cell types of hematopoietic origin and some epithelial cell 
types. Both receptors and their downstream signaling pathways are necessary for the 
regulation of inflammatory responses and host cell defense against chlamydial infection 
(Zou et al., 2016). 
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Figure 3. NOD-dependent inflammatory responses during chlamydial infection. After 
Chlamydia internalisation, cell wall molecules interact with NOD receptors, which will recruit 
the adaptor protein RIP2. RIP2 then mediates the activation of the IKK complex and MAPK 
pathway. The IKK complex can mediate the activation and nuclear translocation of NF-Κβ and 
the subsequent production of inflammatory chemokines, such as IL-8 and type I interferons. 
 
 
1.1.2.3  Host innate adaptive response 
The secretion of cytokines and chemokines by infected epithelial cells can recruit antigen-
presenting cells (APC), such as macrophages and dendritic cells (DCs) to the site of 
infection. APCs maintain the inflammatory response producing more mediators as well 
as help the maturation of T cell, allowing the CD4+ maturation into Th1 cells and its 
interaction with B cells. Activated B cells will produce specific antibodies directed 
against chlamydial proteins. Through antibody-dependent cellular cytotoxicity, CD8+ T 
cells can lyse infected cells marked by antibodies attached to their surface, and opsonized 
elementary bodies are eliminated as antibody-antigen complexes through phagocytosis. 
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1.1.2.4  Persistence and immune response avoidance 
Chlamydiae have evolved mechanisms to overcome the host immune response and persist 
inside the host. As an intracellular pathogen, its detection represents a challenge to the 
immune system. In its development, Chlamydia is confined within a membrane bound 
compartment protected from digestion, making the peptide recruitment for host MHC 
class II difficult. During stress, Chlamydia can enter a persistent state with low metabolic 
activity and replication. This state can lead to a decrease in pro-inflammatory cytokine 
production and consequent decline of inflammation intensity and other immune responses 
(Mpiga and Ravaoarinoro, 2006). Persistent chlamydial particles are hidden in host cells 
avoiding detection through humoral-mediated immunity. Chlamydia have also been 
shown to inhibit apoptosis in infected host cells, as well as having the capacity to 
manipulate several key steps of the host cell immune response. The chlamydial tail-
specific protease (Tsp) can cleave NF-kB into two fragments, one of them retaining the 
ability to bind to DNA, but lacking the transactivation potential. Other antimicrobial 
mechanism that chlamydial infection can affect is the interferon production, including 
IFN-γ, which is associated with protection against viral, bacterial and protozoal 
infections. IFN-γ is linked to host cell tryptophan depletion, through activation and 
expression of the enzyme indoleamine 2-3 dyoxygenase (IDO) (Ziklo et al., 2016). As 
some Chlamydia strains are tryptophan auxotroph, the inhibition of IFN-γ production and 
tryptophan depletion favour persistence and growth of these strains. To protect infected 
cells from detection by lymphocytes, Chlamydiae can inhibit IFN-g-inducible MHC class 
expression and other mechanisms required for MHC gene activation (Zhong, 2009). 
These mechanisms therefore present a challenge for chlamydial detection and elimination 
by the immune system, leading to persistent infection. 
 
 
1.1.2.5  Epidemiology 
Chlamydia trachomatis is the most common cause of sexually transmitted bacterial 
infection worldwide with an estimated 130 million new cases annually (WHO). The large 
percentage of asymptomatic infections represents an ongoing source for efficient disease 
transmission. In the US, the Centers for Disease Control and Prevention studied the 
prevalence of genital Chlamydia in US population aged 14-39 years, between 2007-2012. 
The overall prevalence of Chlamydia among people aged 14–39 years was 1.7%, varying 
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by age and race/ethnicity. In women between 14-24 years, there was a higher prevalence 
of 4.7% (CDC, 2015). C. trachomatis infection is also a leading cause of pelvic 
inflammatory disease (PID) and female infertility, being attributed a 20-30% per cent of 
PID cases to this infection (Soper, 2010). 
 
Blinding trachoma prevalence has also been a subject of extensive study. It is believed to 
be endemic in 56 countries and is the most prevalent in sub-Saharan Africa and East 
Africa. In the present day, trachoma has been reduced to developing countries as its 
prevalence has radically decreased in Europe and North America since the first half of 
the 20th century. It is currently estimated that 1.3 million people developed blindness due 
to C. trachomatis (Burton et al., 2009) and it is still the most common cause of blindness 
caused by an infectious agent. 
 
LGV infections had been uncommon in Western countries and its epidemiological data 
is very limited. In the recent years, some countries have experienced an increase in the 
number LGV diagnoses, being around 115% in Spain between 2009 to 2011 (Parra-
Sánchez et al., 2016) and 40% in the UK from 2014 to 2015 (Childs et al., 2015). Human 
Immunodeficiency Virus (HIV)-positive men having sex with men (MSM) were the 
studied population with more LGV prevalence. 
 
 
1.1.2.6  Treatment 
The high percentage of asymptomatic infection, both in males and females, promotes 
chlamydial spread and the increase of clinical costs associated with this infection. 
Unfortunately, there is currently no specific effective vaccine for Chlamydia infection in 
humans (Igietseme, Eko and Black, 2011; de la Maza, Zhong and Brunham, 2017). The 
increased risk of transmission and co-infection with HIV, gonorrhea and HPV (Human 
Papilloma Virus) is an added cause for concern. Uncomplicated Chlamydia infection is 
normally treated with antibiotics. The standard anti-chlamydial treatments that are used 
are the macrolide azithromycin and the tetracycline doxycycline, with the macrolide 
erythromycin as the most used alternative treatment (Geisler, 2007)(Table 1). 
Tetracyclines are effective protein synthesis inhibitors that prevent the association of 
aminoacyl-tRNA with the bacterial ribosome, interfering with amino acid translocation 
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during translation and protein assembly by binding to a high-affinity binding site in the 
ribosomal 30S subunit. The absence of major anti-eukaryotic activity explains the 
selective antimicrobial properties of tetracyclines (Chopra and Roberts, 2001). Although 
mammalian cells have poor accumulation of these antibiotics and there is a relatively 
weak inhibition of protein synthesis supported by eukaryotic ribosomes, mitochondrial 
protein synthesis is affected (Moullan et al., 2015). Azithromycin and the usual 
alternative antimicrobial treatment, erythromycin, shares the same mode of action as 
tetracyclines, bacterial protein synthesis inhibition, but by binding to the 50S ribosomal 
subunit. A meta-analysis of 12 randomized clinical trials of azithromycin versus 
doxycycline for the treatment of urogenital chlamydial infection demonstrated that the 
treatments were equally efficacious, with microbial cure rates of 97% and 98%, 
respectively (Geisler et al., 2015). Erythromycin treatment is often associated with 
gastrointestinal side effects that can lead to non-adherence with treatment, which makes 
it less ideal than tetracycline treatment (Workowski, Bolan and Centers for Disease 
Control and Prevention, 2015). The described treatments are currently effective as no 
antibiotic resistance has yet been reported in human Chlamydia trachomatis infection. 
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Table 1. Recommended treatment regimens and alternative regimens for C. 
trachomatis infection in non-pregnant patients. (Workowski, Bolan and Centers for 
Disease Control and Prevention, 2015). 
 
 
Recommended regimens Alternative regimens 
Azithromycin 1g orally in a single 
dose 
Erythromycin base 500mg or Erythromycin 
ethylsuccinate 800mg orally 4 times a day 
for 7 days 
Doxycycline 100mg orally twice a 
day for 7 days 
Levofloxacin 500mg orally once daily for 7 
days 
 Ofloxacin 300mg orally twice a day for 7 
days 
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1.1.3  Waddlia chondrophila 
Waddlia chondrophila is a Chlamydia-like intracellular bacteria, which shares a biphasic 
life cycle with the other chlamydial species. Waddlia is a genus of bacteria within its own 
family, which belongs to the Chlamydiae phylum. Waddlia chondrophila was first 
isolated from tissues of aborted bovine foetus at the Washington Animal Disease 
Diagnostic Laboratory by Dilbeck et al. in 1986. When it was first studied by light 
microscopy, it was clear that the microorganism was multiplying inside a cytoplasmic 
vacuole in the host cell, exhibiting structural characteristics compatible with those of 
Rickettsiae and Chlamydiae. Serological identification with monoclonal and polyclonal 
antisera to a variety of Rickettsia, Coxiella, Wolbachia, Anaplasma or Chlamydia spp. 
(Dilbeck et al., 1990) failed to help taxonomical classification. Genomic studies were 
then carried out focusing on the 16S ribosomal DNA gene sequences (Rurangirwa et al., 
1999). 16S rDNA sequence analysis indicated that Waddlia chondrophila was closely 
related to the members of the order Chlamydiales, having 84.5-85.3% sequence 
similarity. This degree of similarity was high enough to allow W. chondrophila’s 
inclusion in the order Chlamydiales but not to justify its inclusion in the Chlamydiaceae 
family (Everett and Andersen, 1997; Everett, Bush and Andersen, 1999). Waddlia 
chondrophila has shown biochemical and antigenic differences to other families of the 
phylum. Contrary to Chlamydiceae species, W. chondrophila is resistant to penicillin. W. 
chondrophila and other Chlamydia-like organisms exhibited better survival rates in host-
free conditions or under heat exposure compared to C. trachomatis (Coulon et al., 2012). 
Other difference between Waddlia chondrophila and chlamydial development in the host 
cell is the level of cytoskeletal arrangement modification in the host cell during infection. 
C. trachomatis inclusions are tightly embedded in cytoskeletal elements, whereas in 
Waddlia, cytoskeleton arrangement around the inclusions were less pronounced (Dille et 
al., 2015). Contrarily to other Chlamydiales, W. chondrophila evades the endocytic 
pathway and co-localize with the mitochondria and endoplasmic reticulum. Waddlia 
chondrophila does not depend on Golgi apparatus fragmentation during infection, 
although this process is important for chlamydial replication (Heuer et al., 2009; Dille et 
al., 2015). Waddlia recruits the mitochondria to a much larger extent than other 
Chlamydia species, allowing the access to large quantities of lipids and ATP. Genetic 
analysis has revealed higher biosynthetic abilities for essential compounds such as 
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nucleotides and amino acid synthesis in Waddlia chondrophila than in other Chlamydia 
species, suggesting less host dependency. 
 
 
1.1.3.1  Clinical manifestations 
The natural host of Waddlia chondrophila is not known. After the isolation of Waddlia 
chondrophila from aborted bovine foetuses, several studies were carried out to determine 
the association between Waddlia chondrophila and abortion. Baud et al. performed a 
study between 2006 and 2009 on women given a diagnosis of an acute episode of 
miscarriage and women having uneventful pregnancies without previous history of 
miscarriage, stillbirth or preterm labour. The study confirmed an association between 
miscarriage and the presence of W. chondrophila (Baud et al., 2014).  Identification of 
W. chondrophila in the human genital region pointed to a sexual transmission and 
infection. A serological study based on the presence of sexually transmitted Chlamydia 
trachomatis and Waddlia chondrophila was performed (Baud et al., 2007) to identify any 
correlation that would confirm the possible sexual transmission of W. chondrophila. The 
absence of this correlation suggested that W. chondrophila is not sexually transmitted. 
However, DNA from this Chlamydia-like organisms has also been found in respiratory 
samples from patients with community-acquired pneumonia suggesting a possible role in 
human respiratory disease (Haider et al., 2008). Some studies have also shown an 
association between contact with animals and positive serologic results for Waddlia, 
raising its zoonotic potential (Corsaro and Greub, 2006; Baud et al., 2007). Furthermore, 
standing well water could also be an important potential reservoir and a possible infection 
source of W. chondrophila (Codony et al., 2012). 
 
 
1.1.3.2  Host cell response 
As with other members of the Chlamydiales order, attachment and entry in the host cell 
is essential for survival and replication. Little is known about the host cell response to 
infection and about the molecules implicated in the adhesion of Waddlia chondrophila to 
its host cell. In Chlamydia, several bacterial proteins have been identified in adhesion, 
such as the major outer membrane protein (MOMP) and OmcB. A study of the genome 
of Waddlia chondrophila revealed the existence of a novel outer membrane protein 
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(OMP) family comprising 11 putative β-barrel proteins or porins (Bertelli et al., 2010). 
The presence of a modified OmcB gene and HSP60 gene was also found, pointing to 
similar entry interactions with Chlamydia spp. W. chondrophila also possess a Type III 
secretion system, sharing almost all its encoding genes with other Chlamydia species. 
Bertelli et al., found that the effectors injected by Waddlia T3SS were different from 
those injected by other species in the Chlamydiaceae family. Only one effector was found 
that was common to both Chlamydia species and Waddlia, Pkn5. The innate immune 
response to infection to W. chondrophila infection was established in the ovine 
trophoblast cell line AH-1, showing a high similarity to the one obtained after infection 
with Chlamydia abortus (Wheelhouse et al., 2009). An induction of the expression of IL-
8 and TNF-a as a result of W. chondrophila infection was found (Wheelhouse et al., 
2014). It was also shown that IL-8 production was dependent on active infection and 
intracellular invasion, as UV-killed W. chondrophila failed to induce IL-8 production in 
AH-1 cells. The decrease in IL-8 production was also found in UV-killed C. trachomatis 
L2 cells, which was shown to be a result of the intracellular association between TLR2 
and the chlamydial inclusion (O’Connell et al., 2006). The lack of IL-8 production after 
UV-killed C. trachomatis and W. chondrophila exposure suggest that host cell response 
against chlamydial infection is primarily triggered by intracellular receptors, such as 
NOD1, rather than by cell surface receptors. Other receptors have been proposed to elicit 
IL-8 release after PRR recognition, as IL-8 production was also found in W. chondrophila 
infected wild-type HEK293 cells, which do not express TLR2 or NOD2, and NOD1 only 
at very low levels (Storrie et al., 2016). In addition, the proinflammatory cytokine IL-1b 
was found to be produced by host cells exposed to UV-killed W. chondrophila indicating 
the stimulation of different immune pathways by the pathogen. More studies still need to 
be performed to compare mechanisms underlying the innate and adaptive immune 
response to Waddlia chondrophila and Chlamydia spp. 
 
 
1.1.3.3  Persistence and immune response avoidance 
Persistence in the host cell under stress situations has been observed in W.  chondrophila 
infection (Vasilevsky et al., 2015), although it is expected to be maintained through 
differential pathways than in Chlamydia infection. The growth of W. chondrophila in 
different host cell lines, such as the endometrial Ishikawa cells, was studied (Kebbi-
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Beghdadi, Cisse and Greub, 2011). A decrease in the pathogen replication and the 
spontaneous appearance of large aberrant bodies was seen in Ishikawa cells, both 
processes being often associated to persistence. After internalization, W. chondrophila 
could avoid the host endocytic pathway as occurs with the other members of the 
Chlamydiaceae family. W. chondrophila was found to be more virulent than C. 
trachomatis as it was less host dependent. Some characteristic features of Chlamydia 
infection and persistence, such as inhibition of host cell apoptosis, are also not observed 
during W. chondrophila infection. 
 
 
1.1.3.4  Epidemiology 
Approximately 15% of pregnancies end in miscarriage, although the cause is identified 
in only 50% of these cases. Waddlia chondrophila infection has been associated with 
human miscarriage. Seroprevalence of W. chondrophila was higher for women who had 
sporadic (31.9%) and recurrent (33.0%) miscarriages than for women who had uneventful 
pregnancies (Baud et al., 2007, 2014)(Baud et al., 2014). In 2015, a study investigating 
seroprevalence of W. chondrophila in subfertile women was performed by Verweij et al. 
(Verweij et al., 2015). A higher seroprevalence of 45.5% was found in this instance and 
therefore, more studies need to be performed on a larger scale to determine the prevalence 
and morbidity of miscarriages caused by this pathogen. The role of Waddlia chondrophila 
in miscarriage is not fully understood and thus there are no established screening 
programs to evaluate the risk of having a miscarriage due to the presence of Waddlia 
chondrophila. 
 
 
1.1.3.5  Treatment 
Waddlia chondrophila infection is normally only detected after infertility has been 
diagnosed or a miscarriage has occurred. As a result, there is no established treatment for 
W. chondrophila infection. Previous research has reported W. chondrophila resistance to 
penicillin, in contrast to many other Chlamydia species. Goy et al., tested the antibiotic 
susceptibility of W. chondrophila in vitro and found it was susceptible to the most 
commonly used treatments for Chlamydia infection, azithromycin and doxycycline (Goy 
and Greub, 2009). In contrast, the pathogen exhibited resistance to quinolones and β-
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lactams. Azithromycin is therefore a potentially effective treatment for Waddlia 
chondrophila infections due to its proven efficacy against other members of the order 
Chlamydiales. However, as W. chondrophila has been found after unsuccessful 
pregnancies, doxycycline is unlikely to be used pre-birth, given its contraindications in 
pregnant patients. What is clear is that more research needs to be performed to establish 
the activity of these antibiotics against W. chondrophila in vivo. 
 
 
1.2  Antimicrobial resistance 
Antimicrobial resistance is the ability of microbes to resist the effects of drugs. This 
resistance allows the pathogen to survive and continue its growth. Antimicrobial 
resistance is a global concern as it directly results in increased morbidity, mortality and 
costs of health care. Antibiotics are drugs predominantly used to prevent and treat 
bacterial infections. When the bacteria develop mechanisms to resist the treatment, 
antibiotic resistance occurs, resulting in a harder to treat infection. Antibiotic resistance 
is a natural process of bacterial evolution, which can be slowed with prevention and the 
appropriate use of antibiotics, but not stopped. Therefore, there is an urgent necessity to 
find new antimicrobial drugs, with low toxicity and a low likelihood of engendering 
antimicrobial resistance. 
 
 
1.2.1   Antibiotic resistance in Chlamydia species 
There are relatively few documented reports of antibiotic resistance in Chlamydia and no 
examples of natural and stable antibiotic resistance in strains collected from humans 
(Sandoz and Rockey, 2010). Several clinical isolates have shown resistance to antibiotics 
but these strains either lost their resistant phenotype in vitro or their viability. Antibiotic 
resistance has not emerged yet in human chlamydial infection although a stable 
tetracycline-resistance phenotype has been described in Chlamydia suis isolates from ill 
and apparently healthy pigs (Donati et al., 2016). The possibility of horizontal transfer of 
tetracycline-resistance from C. suis to clinical strains of Chlamydia trachomatis in vitro 
has been object of study (Suchland et al., 2009). Horizontal transfer of tetracycline-
resistance was observed, pointing to a future possibility of it in a naturally occurring C. 
trachomatis strain. Although antibiotic resistance in Chlamydia trachomatis is still rare, 
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there has been considerable recent concern about the efficacy of treatments for urogenital 
and anorectal forms, and the efficacy of the most frequent treatment, azithromycin. 
Recent meta-analysis of treatment efficacy for urogenital C. trachomatis infection 
between azithromycin and doxycycline revealed a significant efficacy difference in 
favour of doxycycline (Kong and Hocking, 2015). Another meta-analysis was performed 
in 2015 in instances of anorectal infections revealing a higher reduction in the efficacy of 
azithromycin (efficacy of 83%, with 95% efficacy being the threshold recommended by 
the World Health Organisation, WHO for STI treatments). Alternatives are needed as 
there is not a vaccine available to prevent Chlamydia infection in humans and the most 
used treatment may be subject of resistance in the future.	  
 
 
1.3  Cationic Host Defence Peptides 
Host defence peptides (HDPs; also known as antimicrobial peptides), are peptides that 
have broad antimicrobial and immunomodulatory activity. They are key components of 
the innate immune system, with potent microbicidal, antiviral and immunomodulatory 
properties (Hemshekhar, Anaparti and Mookherjee, 2016).	   HPDs can be found in a 
variety of life-forms, including prokaryotes and eukaryotes. The first reported animal-
originated HDP is a defensin, which was isolated from rabbit leukocytes in 1956 
(HIRSCH, 1956). In total, more than 2,600 HDPs have been discovered or characterised 
up to date. In animals, HDPs are normally produced in tissues and organs that are exposed 
to pathogens. They are believed to be the first line of defence in the innate immune 
response against bacteria, viruses and protozoa. Although there is great sequence 
diversity among HDPs, there are structural elements that are shared by most of them. 
They are small amphipathic peptides, typically 12-50 amino acids in length, with a net 
positive charge ranging from +2 to +9 due to an abundance of basic amino acids such as 
lysine and arginine (Hemshekhar, Anaparti and Mookherjee, 2016). HDPs present 
different secondary structures although two forms are predominant; b-sheet structures 
with disulphide bonds and a-helical structures adopted by linear peptides. A feature 
common to all cationic host defence peptides is that they exert their activity by targeting 
membranes (Mookherjee and Hancock, 2007). The two most well characterized families 
of CHDPs in mammals are cathelicidins and defensins.  
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1.3.1  Defensins 
This family of peptides, originally isolated from leukocytes, is expressed in immune and 
epithelial cells. Defensins are produced by vertebrates and have been also found in plants 
and insects. A common feature of defensins is the three-stranded β-sheet structure, with 
3 disulphide bridges formed between their 6 cysteine residues. Defensins are categorized 
into two main subfamilies, the α and β defensins, which differ in the length of peptide 
segments between the six cysteines and in the pairing of the cysteines that are connected 
by disulphide bonds. A third subfamily has been discovered, the θ defensins. θ defensins 
have a cyclic structure formed from two α defensins. Usually, newly synthesized 
defensins undergo proteolytic cleavage to become active. Most active defensins show 
antimicrobial activity against bacteria and fungi, achieved by their ability to permeabilize 
microbial membranes (Ganz, 2003). 
 
 
1.3.2  Cathelicidins  
Cathelicidins are a family of evolutionary conserved peptides found in a variety of 
species. The discovery of cathelicidins commenced after the isolation of the antimicrobial 
peptide Bac5 from bovine neutrophils, and the finding that they were cleaved from 
inactive precursors (Gennaro, Skerlavaj and Romeo, 1989). Many cathelicidin peptides 
have been described in a substantial variety of animals such as lizards, birds, fish and 
mammals. Cathelicidins range in size, from 12 to 88 amino acids, and are comprised of a 
highly conserved 14 kDa N-terminal cathelin-like pro-domain, followed by a signal 
peptide and a C-terminal ‘mature’ peptide region (Figure 4). The cathelin-like domain is 
highly conserved among species and shares homology with the porcin cathepsin cysteine 
protease inhibitor, the term ‘cathelin’ standing then for cathepsin L inhibitor. The C-
terminal domain is highly divergent and is responsible for the antimicrobial activity of 
the peptide upon proteolytic cleavage. The signal peptide assures the direction of newly 
synthesized peptides towards the secretory pathway. In humans, only one cathelicidin has 
been described, the peptide hCAP18, which is encoded by the cathelicidin antimicrobial 
peptide (CAMP) gene, and is cleaved to the active peptide LL-37. 
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Figure 4. Structure and processing of cathelicidin peptides. Adapted from Shinnar et al., 
(Shinnar, Butler and Park, 2003). Cathelicidins are expressed and synthesized as inactive pro-
peptides. A signal peptidase removes the N-terminal signal peptide. The mature peptide is 
released by further proteolytic processing of the precursor by different processing enzymes, 
removing the cathelin domain. The mature peptide can be cleaved into active fragments.  
 
 
1.3.2.1  hCAP18 (LL-37) 
hCAP18 is encoded by the CAMP gene, which is found on the chromosome 3p21.3 
(Larrick et al., 1996). hCAP-18 is a major protein in specific granules of neutrophils, but 
it is also present in subpopulations of lymphocytes and monocytes, in squamous epithelia, 
epididymis and seminal plasma, in the lung and in keratinocytes during inflammatory 
skin diseases (Sørensen et al., 2001). hCAP18 is cleaved extracellularly by proteinase-3, 
a serine protease, to generate LL-37 which is the dominant cleavage product. LL-37 
structure is linear and composed by 37 amino acids with two leucine residues at the N-
terminal which adopts an amphipathic a-helix structure (Figure 5). Other cell types of the 
immune system that can express LL-37 are macrophages, eosinophils, mast cells, Natural 
Killer, T and B cells (Dürr, Sudheendra and Ramamoorthy, 2006). hCAP-18 can be found 
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in body fluids such as saliva, sweat, blood, semen, milk and airway surface fluids. 
Physiological LL-37 concentration in plasma is approximately 1.2µg/ml (Sørensen et al., 
1997), though this concentration can increase in response to infection to concentrations 
up to 20µg/ml in the airway fluid of infected patients (Barlow et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Amino acid sequence and secondary structure of LL-37. PDB ID: 2K6O (Wang, 
2008). LL-37 secondary structure was obtained by NMR spectroscopy. The three-dimensional 
structure is composed of a curved amphipathic a-helix structure. 
 
 
1.3.2.2  Protegrin-1 
Contrary to humans, other mammals can produce more than one cathelicidin. In the case 
of pigs, they express a variety of cathelicidins which differ in activity and structural 
motifs. The porcine cathelicidins include the protegrins (PGs), the α-helical 
peptides (PMAPs), prophenins and the PR-39 peptide. Antimicrobial activity has been 
well characterized for PR-39 (Agerberth et al., 1991), PMAP-23 (Zanetti et al., 1994), 
PMAP-36 (Scocchi et al., 2005), and PG-1 (Kokryakov et al., 1993). There are five small 
protegrins (16-18 amino acids residues) described (Kościuczuk et al., 2012). As 
cathelicidins, protegrins are proteolytically cleaved into their active forms by neutrophil 
elastase in the extracellular environment. Protegrins present a two-stranded β-sheet 
structure in solution which is linked by a β-hairpin loop stabilized by to intramolecular 
disulfide bonds between cysteines (Figure 6). Protegrin peptides interact strongly with 
lipid bilayer membranes, particularly anionic lipids; protegrins have been shown to form 
pores in lipid bilayers, which can lead to the pathogen death (Bolintineanu and Kaznessis, 
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2011). Protegrins have antimicrobial activity against bacteria, especially Gram-negative, 
fungi, and some enveloped viruses (Sousa et al., 2017). Protegrin-1 is able to retain 
antimicrobial and antifungal properties at physiologic salt concentrations and in the 
presence of serum, conditions in which other cathelicidins would be affected 
(Steinstraesser et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Amino acid sequence and secondary structure of PG-1. PDB ID: 1PG1 (Fahrner et 
al., 1996). PG-1 secondary structure was obtained by NMR spectroscopy. Protegrin-1 form a 
structure composed primarily of a two-stranded antiparallel β-sheet, with strands connected by a 
β-hairpin loop. The red ‘X’ at the end of the peptide sequence represents an unspecified or 
unknown amino acid.  
 
 
1.3.2.3  SMAP-29 
In sheep eight cathelin-associated peptides have been identified, including cyclic 
dodecapeptide, SMAP-28 and 29 and Bac5, 6, and 7.5. The cathelicidin SMAP-29, sheep 
myeloid antimicrobial peptide of 29 residues, possesses an a-helical structure (Figure 7) 
and is one of the most effective HDP known. This peptide possesses broad spectrum 
antimicrobial activity, against both bacteria and fungi. SMAP-29 is produced by several 
cell types, including trophoblasts (Coyle et al., 2016). Dawson et al., studied the 
antimicrobial potential of SMAP-29 against several bacterial and fungal species (Dawson 
and Liu, 2009). They discovered that this peptide inhibits the growth of bacterial 
pathogens, Gram – and Gram +, at a very low MIC (minimum inhibitory concentration, 
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the lowest peptide concentration that prevents growth), proving its potent antimicrobial 
activity. When they were treating Bacillus anthracis infection, the obtained MIC was 0.8-
1.6µM. Very few antimicrobial peptides are active at concentrations lower than this 
(Dawson and Liu, 2008). As with other antimicrobial peptides, high concentrations can 
produce cell cytotoxicity, probably due to its capacity to disrupts membranes. SMAP-29 
is not active in the presence of serum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Amino acid sequence and secondary structure of SMAP-29. PDB ID: 1FRY (Tack 
et al., 2002). SMAP-29 secondary structure was obtained by NMR spectroscopy. The three-
dimensional structure indicated that residues 8-17 were helical, residues 18-19 formed a hinge 
and residues 20-28 formed and hydrophobic segment. 
 
 
1.3.2.4  Immunomodulatory functions of cathelicidins 
Cathelicidins have multiple functions in immunity and inflammation. Some peptides such 
as the human cathelicidin LL-37 have been proposed to have far more potent 
immunomodulatory activities than antimicrobial functions (Turner et al., 1998). It is 
believed that their broad antimicrobial properties are largely attributed to their capacity 
to mediate the immunomodulatory functions. HDPs constitute a link between innate 
defense and adaptive immunity due to their chemotactic activity. Cathelicidins can 
promote chemotaxis of immune cells in an indirect manner by inducing the production of 
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chemokines from immune and epithelial cells. For example, cathelicidins can stimulate 
epithelial cells to release IL-6, as well as cause mast cell degranulation, promoting 
histamine and other cytokines release. LL-37 upregulates inflammatory signaling due to 
its ability to activate cell receptors, such as TLRs (Vandamme et al., 2012). Besides 
chemotaxis, LL-37 has been also found to suppress neutrophil apoptosis, prolonging their 
survival, and potentially protecting the host against the pathogen for a longer period 
(Barlow et al., 2006; Li et al., 2009). The human cathelicidin has also the ability to induce 
dendritic cell differentiation (Yang, Chertov and Oppenheim, 2001) and Th1 cytokine 
production. 
 
 
1.3.2.5  Antibacterial activity of cathelicidins 
Cathelicidins have shown direct antimicrobial activity. The importance of their broad 
antimicrobial activity, against virus, bacteria and fungi is evidenced through an increased 
susceptibility to infection in neutropenic patients, who have less neutrophils and 
consequently a decrease in the cathelicidin concentration (Neth et al., 2005). More 
evidence of the antibacterial activity of cathelicidins is found in mice deficient in 
mCRAMP (mouse cathelicidin) which have an increased susceptibility to infection of the 
skin, urinary tract and gastrointestinal tracts (Iimura et al., 2005; Chromek et al., 2006). 
Experimental systems simulating physiologically conditions and in vivo animal model 
infections have demonstrated how CHDP are able to limit or clear infections (Barlow et 
al., 2010). All cathelicidins are positively charged and amphipathic. The positive charge 
allows them to interact with negatively charged phospholipids in target membranes. Their 
partial hydrophobicity is important for its subsequent insertion into the membrane (Figure 
8). The peptide insertion in the membrane leads to the formation of membrane pores that 
cause an unrestricted flux of ion and other molecules from the cytoplasm (Dawson and 
Liu, 2009; Bolintineanu and Kaznessis, 2011). The antiviral activity of cathelicidins has 
been also studied, although not as broadly as in bacteria, suggesting that cathelicidins 
may prove to play significant roles in defense against viral infections (Barlow et al., 
2014). 
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Figure 8. Example of cathelicidin (PG-1) pore formation in a phospholipidic membrane. 
(Bolintineanu and Kaznessis, 2011). After adsorption to the surface of anionic bacterial 
membranes, the peptide inserts into the membrane core. Oligomerisation of peptides to form 
aggregates leads to transmembrane pore that will cause uncontrolled ion and contents leakage 
leading to bacterial death.  
 
 
1.3.2.6  Antibacterial activity of cathelicidins in Chlamydia infection 
The effect of different cathelicidins on Chlamydia has been previously studied. The 
porcine CHDP, Protegrin-1, was found to have strong anti-chlamydial activity against C. 
trachomatis (Chong-Cerrillo et al., 2003) inhibiting infectivity by 50% at a concentration 
of 6µg/ml. The antimicrobial activity of other cathelicidin peptides (SMAP-29 from 
sheep, LL-37 from humans, BMAP-27 and BMAP-28 from cattle apart from Protegrin-
1) was tested against a total of 25 strains from the chlamydial species (Donati et al., 2005). 
It was observed than C. trachomatis was more susceptible to peptides than C. pneumoniae 
strains. SMAP-29 was found to be the most active peptide among various chlamydial 
species, including C. trachomatis and C. pneumoniae. Donati et al. also tested the same 
cathelicidins against Simkania negevensis, Gram-negative bacteria belonging to the 
family of Simkaniaceae in the order Chlamydiales. S. negevensis was not sensitive to LL-
37, even at very high concentrations of the peptide (80  µg/ml). On the contrary it was 
found to be susceptible to the other tested peptides at very low concentrations (1 to 
0.1µg/ml). These results suggested a higher susceptibility of Simkania negevensis than 
other members of Chlamydiales (Donati et al., 2011). However, to date, no studies have 
been performed to study the antimicrobial effects of cathelicidins in Waddlia 
chondrophila infection. 
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1.4  Hypothesis 
Cathelicidins have shown a broad antibacterial spectrum and effectiveness against 
different bacteria and have been previously study in Chlamydia infection with promising 
results. In vitro, different Chlamydia species have been shown to be susceptible to 
cathelicidins (Yasin et al., 1996; Chong-Cerrillo et al., 2003; Donati et al., 2005, 2010). 
The direct effect of HDPs has been the most studied. Their indirect antimicrobial effects 
have been recognized, in addition to direct microbicidal activity, and are believed to be 
key in the control of inflammation (Yang et al., 2004).  
 
Waddlia chondrophila has been proposed as possible model for Chlamydia infection 
thanks to its faster life cycle and its higher virulence. We hypothesise that direct 
cathelicidin exposure would have an impact on Chlamydia trachomatis and Waddlia 
chondrophila population, decreasing its replication and infectivity. This study will also 
focus on the effects of cathelicidin treatment in inflammation and host cell protection 
against infection, which we expect to be modulated due to the broad immunomodulatory 
properties of cathelicidins. The effect of the different cathelicidin treatment on host cell 
death will also be study to assess their toxicity.  
 
 
1.5  Research Aims 
 
I.   To assess the direct effect of LL-37, PG-1 and SMAP-29 on C. trachomatis and W. 
chondrophila infectivity and replication. 
 
II.   To study the indirect effect of LL-37, PG-1 and SMAP-29 on C. trachomatis and W. 
chondrophila infectivity and replication. 
 
III.   To study the effect of the different cathelicidin treatments on host cell death. 
 
IV.   To investigate the host inflammatory response after the different cathelicin treatment 
on C. trachomatis and W. chondrophila infection. 
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1.6  Research Objectives 
 
I.   To achieve aim I, we will use in vitro models of C. trachomatis and W. chondrophila 
infection and subject both the pathogens to varying concentrations of peptides prior 
to host cell infection. Bacterial concentrations and infectivity will then be assessed 
by molecular quantification (DNA quantification) and by immunostaining of 
intracellular inclusions respectively.  
 
II.   To achieve aim II, in vitro models of C. trachomatis and W. chondrophila infection 
will be used. The host cells will be exposed to varying concentrations of peptides 
prior to infection. Bacterial concentrations and infectivity will be assessed by 
quantitative PCR and immunostaining.  
 
III.   To accomplish aim III, we will use the same in vitro epithelial host cell model as in 
aim I and II. Bacteria will be exposed to varying concentrations of peptides prior to 
host cell infection. Afterwards, the bacteria and the peptides will be added to the host 
cell monolayers and incubated. To assess if the cathelicidin treatments caused host 
cell death, supernatants will be recovered and analysed by lactate dehydrogenase cell 
death assay.  
 
IV.   To achieve aim IV, we will use in vitro models of C. trachomatis and W. 
chondrophila infection and subject both the pathogens to varying concentrations of 
peptides prior to host cell infection. In parallel, the host cells will be also exposed to 
the peptides prior to infection with both pathogens. Supernatants will be recovered 
and analysed by Enzyme Linked ImmunoSorbent Assay to investigate the host cell 
inflammatory response. 
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2  Materials and methods  
 
 
2.1  Cell culture 
The human epithelial cell line, HEp2, was obtained from the European Collection of Cell 
Cultures (ECACC, Salisbury, UK). HEp2 were routinely grown in Iscove’s Modified 
Dulbecco’s Medium (IMDM, Life Technologies, Paisley, UK) supplemented with 5% 
heat inactivated foetal bovine serum (FBS, Life Technologies, Paisley, UK) and 0.1% 
Gentamycin (10mg/dL) (Life Technologies, Paisley, UK). Cells were grown at 37oC in a 
heated, humidified incubator with 5% CO2. Cells were passaged every 3-4 days and cell 
counts were performed using a hemocytometer to determine seeding density. 
 
 
2.2  Cathelicidins 
Cationic Host Defence Peptides (CHDP) were provided through a collaborative 
agreement with the Biotechnology Core Facility at the US Centers for Disease Control & 
Prevention (Atlanta, GA, USA). The peptides were assembled using the Fmoc/tBu solid-
phase peptide synthesis approach (Zughaier et al., 2010) using either model 433A 
(Applied Biosystems, CA, USA) or model Liberty (CEM Corporation, NC, USA) 
automated peptide synthesizers followed by cleavage in the trifluoroacetic acid (TFA) / 
phenol / thioanisole / ethanedithiol/water (10∶0.75∶0.5∶0.25∶0.5, w/w) mixture at 25°C 
for 90 minutes followed by precipitation with cold diethyl ether. The crude peptides were 
purified by preparative reversed-phase high-pressure liquid chromatography (RP-HPLC). 
The peptide purity (>98%) was confirmed by analytical RP-HPLC, and the masses were 
confirmed by mass spectrometry. Following lyophilisation, the purified peptides were 
obtained in the form of their TFA salts. The peptides used for the experiments were the 
human cathelicidin LL-37 peptide (sequence 
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES), scrambled LL-37 (sequence 
RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL), porcine cathelicidin 
Protegrin-1 (sequence RGGRLCYCRRRFCVCVGRX) and the sheep cathelicidin 
SMAP-29 (sequence RGLRRLGRKIAHGVKKYGPTVLRIIRIAG). All the peptides 
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were dissolved in endotoxin-free water (Sigma-Aldrich, Dorset, UK) and stored at -20oC 
until use. 
 
 
2.3  Chlamydia trachomatis and Waddlia chondrophila propagation 
Waddlia chondrophila strain ATCC VR-1470 was grown at 37°C in HEp2 cells, with 
Infectious Media (IM) which consisted of IMDM supplemented with 2% heat inactivated 
FBS and cycloheximide (1µg/ml final concentration). After 72 hours, the cell monolayers 
were disrupted with cell scrapers and the medium containing cell debris was removed, 
before centrifugation at 50×g for 5 minutes at 4°C to remove intact cells. The supernatant 
was removed and centrifuged 10 minutes at 20,000×g. The pellet was resuspended in ice-
cold sucrose-phosphate-glutamic acid (SPG) buffer (10mM, pH 7.4), aliquoted into 
microcentrifuge tubes and stored at −80°C. To quantify viable organisms, aliquots were 
thawed at room temperature and titrated on HEp2 cells.  
Chlamydia trachomatis serovar LGV II strain ATCC VR-902B was grown at 37°C in 
HEp2 cells, with IMDM supplemented with 2% heat inactivated FBS and cycloheximide 
(1µg/ml final concentration). After 72 hours, cell monolayers were disrupted with cell 
scrapers and the medium containing the cell debris was centrifuged at 2851xg for 10 
minutes to pellet the infected cells. The supernatant was discarded and the pellet was 
resuspended in 1-2ml 10% ice cold PBS. Glass beads were added to the solution and it 
was then vortexed for 1 minute. The solution was centrifuged at 233xg for 5 minutes and 
the supernatant was aliquoted in microcentrifuge tubes adding an equal amount of filtered 
4SP buffer (Sucrose 0.67mM; Na2HPO4 80.4µM, pH 7.1) and stored at -80ºC.  
 
 
2.4  Determination of bacterial titer 
HEp2 cells were seeded at a density of 5x104  cells per chamber in 8 well chamber slides 
(BD Falcon, Becton Dickinson, Bedford, UK) and grown to 80-90% confluency. Serial 
dilutions (10-fold) of the obtained aliquots from the bacterial propagation were prepared 
from a -2 to a -8 dilution factor in IM. Culture media was aspirated before addition of 
250µl of each serial dilution to each chamber. Cells were incubated with the bacteria for 
1 hour at 37ºC. Infectious supernatant was aspirated and replaced with fresh culture 
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media. After 24 hours the medium was removed, cells were fixed in acetone, air-dried, 
and the slides were frozen at −20°C prior to analysis by fluorescent 
immunocytochemistry. To obtain the number of bacteria per ml of the stock aliquots, 
inclusions were counted in two chambers corresponding to two different serial dilutions 
with a countable average number bacterial inclusions (20~200). The average number 
obtained was then transformed using the dilution factor used and then multiplied by four 
to obtain the final concentration of bacteria per ml of the stock aliquots. 
 
 
2.5  Direct cathelicidin treatment of C. trachomatis and W. chondrophila  
HEp2 cells were seeded at a density of 5x104 cells per chamber in 8 well chamber slides 
(intracellular bacterial inclusions immunostaining assays) or at a density of 2x105 per well 
in 24 well plate (bacterial quantification through real-time PCR assays) and grown to 80-
90% confluency. 
 
Waddlia chondrophila was diluted to a Multiplicity of Infection (MOI) of 1 and C. 
trachomatis was diluted to a Multiplicity of infection (MOI) of 0.01 in serum-free IMDM 
media and incubated for 1 h at 37ºC with various concentrations of LL-37, PG-1 and 
SMAP-29: 0µg/ml, 10µg/ml, 25µg/ml, 50µg/ml and 100µg/ml. A 1:10 dilution of these 
concentrations was prepared in 2% FBS supplemented IMDM was carried out prior 
addition to cells for a further 1 h incubation at 37ºC. Media with bacteria was then 
aspirated and replaced with 5% FBS supplemented IMDM for 24 hours at 37ºC. 
Following the last incubation, monolayers grown in the 24-well plate were chemically 
lysed and DNA extraction was performed. Immunostaining was performed in parallel 
monolayers grown in chamber slides. Supernatants were recovered and stored at -80ºC. 
LL-37, PG-1 and SMAP-29 treatments were performed independently.  
 
 
2.6  Host cell exposure to cathelicidins prior infection  
HEp2 cells were seeded at a density of 5x104 cells per chamber in 8 well chamber slides 
(intracellular bacterial inclusions immunostaining assays) or at a density of 2x105 per well 
in 24 well plate (bacterial quantification through quantitative PCR, qPCR, assays) and 
grown to 80-90% confluency. 
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LL-37, PG-1 and SMAP-29 were diluted in serum-free IMDM to various concentrations 
(0µg/ml, 1µg/ml, 5µg/ml and 10µg/ml) and incubated for 1 hour at 37ºC with the HEp2 
host cells. LL-37, PG-1 and SMAP-29 treatments were performed independently. Host 
cell monolayers were then washed once with 1X PBS and then infected at identical MOIs 
than when they were infected with cathelicidin treated bacteria (Results Part 2.6) for 1 
hour at 37ºC. After infection, media with bacteria was discarded and replaced with 5% 
FBS supplemented IMDM, and cells were incubated for 24 hours at 37ºC. Following the 
last incubation, monolayers grown in 24-well plate were lysed and DNA extraction was 
performed. Immunostaining was performed in parallel in monolayers grown in chamber 
slides. 
 
 
2.7  DNA extraction  
DNA was extracted using an DNeasy® Blood and Tissue Kit (Qiagen, Crawley, UK) 
according to manufacturer’s protocol. Cell monolayers used for quantitative PCR analysis 
were lysed directly in 200µl AL Lysis buffer (supplied with DNeasy Blood and Tissue 
kit). The lysate was mixed sequentially with 200µl PBS and 20µl Proteinase K before 
incubation at 56°C for 30 minutes. Absolute ethanol (200µl) was added to each sample 
and then added to DNA extraction columns. Following manufacturer’s instructions, DNA 
extraction was carried out and extracted DNA was then suspended in Elution Buffer 
(Qiagen). Until analysis, the extracted DNA samples were stored at -20ºC. The quality of 
the extracted DNA was analysed using a NanoDrop Spectrophotometer (Thermo Fisher 
Scientific, Loughborough). 
 
 
2.8  Real-Time PCR 
A pan-Chlamydiales qPCR targeting the 16S rRNA gene was performed to quantify the 
replication of the organism in culture. The qPCR assays were performed as previously 
described by Lienard et al. (Lienard et al., 2011). using the forward primer panCH16F2 
(5´-CCGCCAACACTGGGACT-3´), the reverse primer panCh16R2 (5′-
GGAGTTAGCCGGTGCTTCTTTAC-3′) and the probe panCh16S (5′-FAM-
CTACGGGAGGCTGCAGTCGAGAATC-BHQ1-3′). Assays were performed in a total 
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volume of 20µl, using the PrecisionPlus 2X qPCR MasterMix Low ROX and inert blue 
dye (Primerdesign, Southampton, UK), 0.1µM primer (Exiqon, Vedbaek, Denmark), a 
0.1µM probe (Integrated DNA Technologies, Iowa, USA), molecular biology grade water 
and 2µl DNA. The PCR products were detected with a StepOnePlus Real-Time PCR 
System (ThermoFisher Scientific, UK). Molecular grade water was used as a negative 
PCR control. Quantification was achieved using a standard curve derived using a 
recombinant plasmid control (purified from a Parachlamydia acanthamoebae bacterial 
culture) as previously described by Lienard et al. 2011. 
  
 
2.9  Immunostaining of bacterial inclusions 
Host cell monolayers grown in chamber slides were fixed with ice-cold acetone for 5 
minutes. Acetone was removed by aspiration and the slides were left to air dry prior 
freezing at -20ºC for a minimum of 20 minutes. Slides were removed from −20°C storage 
and rehydrated in 1X PBS until room temperature (RT). The slide chambers were then 
removed for immunostaining. Slides were blocked in a 2% BSA in PBS solution for a 
minimum of 30 minutes at RT. The slides were washed 3X in PBS prior to addition of 
primary antibodies, rabbit anti-W. chondrophila serum and mouse anti-C. trachomatis-
LPS overnight at 4oC at a 1:2000 dilution (in 1X PBS). After a further washing step, the 
slides were incubated with the secondary antibody, a goat anti-rabbit TRITC and anti-
mouse ALEXA 594 respectively, in a 1:1000 dilution (in 1X PBS) for 1 hour at RT. After 
another washing step, host cell actin filaments stain was performed using ALEXA 488 
Green Phalloidin (Life technologies, Paisley, UK). Slides were washed and mounted 
using Vectashield anti-fade mounting medium containing DAPI (Vector Laboratories, 
Peterborough, UK). Slides were examined using a digital imaging system with an 
Axioscope fluorescent microscope (Carl Zeiss Ltd, UK) equipped with GFP, RFP and 
DAPI fluorescent filter sets for inclusion counting. For image capture slides were further 
examined using a LSM 800 confocal microscope (Carl Zeiss Ltd, UK). 
 
 
2.10   Lactate Dehydrogenase assay 
Recovered supernatants from experiments described in Results section 2.6 were analysed 
by transferring 50µl of the supernatant to a 96-well flat bottom plate in duplicate. Lactate 
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Dehydrogenase release from host cells was then measured by a CytoTox 96® Non-
Radioactive Cytotoxicity kit (Promega, Madison, USA). A positive control for LDH 
release was obtained by exposing uninfected host cell monolayers to 0.01% Triton-X in 
PBS. 50µl of reconstituted substrate mix, provided by kit, was added to each well and 
plate was incubated for 30 minutes at room temperature protected from light. The Stop 
solution (50µl) provided in the kit was added to each well and absorbance was recorded 
at 492nm on DynexÒ microplate reader (Dynex Technologies, Worthing, 
UK).  Absorbances were converted into % of LDH release, considering that the positive 
control (host cell monolayers treated with Triton-X) released 100% of available LDH. 
 
 
2.11   IL-8 Enzyme Linked ImmunoSorbent Assay (ELISA) 
Experiments described in Results sections 2.6 and 2.7, direct cathelicidin treatment of C. 
trachomatis and W. chondrophila and host cell exposure to cathelicidins prior infection, 
were performed using MOI 1 and MOI 0.1 for both W. chondrophila and C. trachomatis 
and supernatants were recovered after 24 hours post infection with W. chondrophila and 
C. trachomatis and after 48 hours post infection with C. trachomatis. Supernatants were 
analysed for the presence of IL-8 by Enzyme Linked ImmunoSorbent Assay 
(ELISA). The IL-8 ELISAs were performed using a DuoSet human CXCL8/IL-8 ELISA 
kit (R&D Systems, Abingdon, UK). All reagents were reconstituted and prepared 
following manufacturer’s instructions and given concentrations. 96-well flat bottom 
plates were coated overnight with the capture antibody provided by the kit. Plates were 
washed with 1X PBS and blocked (1% BSA in PBS, pH 7.2-7.4, 0.2µm filtered) for a 
minimum of 1 hour at room temperature (RT). After a washing step, 100µL of each 
sample was added. A seven-point standard curve was created diluting the reconstituted 
standard reagent 1:2 in Reagent Diluent (0.1% BSA, 0.05% Tween 20 in Tris-buffered 
Saline, 20mM Trizma base, 150mM NaCl, pH 7.2-7.4, 0.2µm filtered) starting at a 
3000pg/ml concentration. 100µL of Reagent Diluent was used as blank. All samples, 
standards and controls were added in duplicate. Supernatant samples were incubated at 
RT for 2 h prior washing step with 1X PBS. The working solution of detection antibody 
in Reagent Diluent was then added to each well and incubated at RT for 2 hours. The 
plate was washed and the working dilution of Streptavidin-HRP was added to each well 
and incubated for 20 minutes at RT. After a further washing step, substrate solution 
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(TMB, ThermoFisher Scientific, UK) was then added to form an enzyme-antibody-target 
complex to produce a measurable signal. After 20 minutes the substrate formation was 
stopped by adding 50µL of Stop solution (2N H2SO4). The optical density of each well 
was determined immediately, using a microplate reader (DynexÒ, Dynex Technologies, 
Worthing, UK) set to 450nm with wavelength correction set to 540nm (this subtraction 
will correct for optical imperfections in the plate). 
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3  Results  
 
 
3.1   The direct antimicrobial effects of cathelicidins on C. trachomatis and W. 
chondrophila 
 
3.1.1   Exposure to LL-37, PG-1 or SMAP-29 reduces Chlamydia trachomatis 
infectivity 
 
To assess whether cathelicidins alter the infectivity of C. trachomatis, bacteria were 
directly exposed to varying concentrations of LL-37, PG-1 and SMAP-29 for 1 hour prior 
to host cell infection. sLL-37, a control peptide with identical amino acid composition 
but scrambled sequence, was used to determine the importance of sequence specificity in 
the peptide activity. At a time point of 24 hours post infection, host cell monolayers were 
fixed. Bacterial inclusions were then immunostained and visualised inside the host cells 
(Figure 9). The number of intracellular inclusions in each treatment was then quantified 
and represented. A gradual decrease in the number of visible inclusions was observed, 
indicating a reduction in C. trachomatis infectivity in the presence of LL-37, PG-1 or 
SMAP-29 treatment (Figure 10A, 10B and 10C). All peptide treatments resulted in a 
statistically significant reduction in the number of inclusions, at varying concentrations 
of each peptide used. PG-1 appeared to display the most effective antimicrobial activity 
at concentrations as low as 10µg/ml, whereas LL-37 and SMAP-29 did demonstrate 
antimicrobial activity, but at higher concentrations. 
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Figure 9. Confocal imaging of the intracellular localisation of bacterial inclusions.   
The human epithelial cell line, HEp2, was infected with C. trachomatis or W. 
chondrophila and fixed with acetone after 24h. Specific immunostaining of the bacterial 
inclusions was performed (A, B and C). Host cell actin filaments were stained by 
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phalloidin (D, E and F) and a DAPI stain of host cell nuclei was performed while 
mounting the slides (G, H and I). Images were generated on a LSM800 Zeiss microscope.	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Average number of quantifiable inclusions after exposure of Chlamydia 
trachomatis to cathelicidins prior to host cell infection. C. trachomatis was incubated for 1 
hour with a range of peptide concentrations prior to infection of HEp2 cell monolayers for an 
additional 1 hour. After 24 hours, immunostaining and counting of the inclusions was performed 
using an inverted fluorescence microscope. Data represents the average number of inclusions 
counted per treatment ± SEM (n=3). Statistical analysis was performed via a one-way ANOVA 
A	   B	  
C	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with Dunnett’s post-hoc test comparing C. trachomatis treated samples to the untreated control 
(0µg/ml). *p£0.05, **p£0.01, *** p≤0.001.  
 
 
3.1.2   Exposure to LL-37, PG-1 and SMAP-29 reduces Chlamydia trachomatis 
replication 
 
To assess whether cathelicidins alter replication of C. trachomatis, the bacteria were 
directly exposed to varying concentrations of LL-37, PG-1 and SMAP-29 for 1 hour prior 
to host cell infection. Following infection, bacterial ribosomal 16S gene copies were 
quantified by qPCR, revealing a decrease in bacterial replication in treatments where 
bacteria were exposed to high concentrations of peptide. (Figures 11A, 11B and 11C).  
Bacterial infection of the cells was highly variable, with measurable average gene copy 
number varying between 19000 copies (0µg/ml SMAP-29) to 120 copies (100µg/ml PG-
1), likely due to a higher sensitivity to PG-1 exposure, also seen in the dramatic decrease 
of C. trachomatis infectivity after PG-1 exposure (Figure 9B).  While LL-37 exposure 
only resulted in a moderate decrease in bacterial gene copy number measured, the ovine 
cathelicidin SMAP-29 induced statistically significant decreases in gene copy number 
even at the low concentration of 25µg/ml.  The porcine cathelicidin PG-1 was also 
moderately effective at reducing 16S gene copy number, although this was not as 
successful as SMAP-29, and was not statistically significant. 
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Figure 11. Average Chlamydiales 16S gene copy number after exposure of Chlamydia 
trachomatis to cathelicidins prior to host cell infection. C. trachomatis was exposed for 1 hour 
to varying peptide concentrations prior to infection of HEp2 cell monolayers for an additional 1 
hour. After 24 hours, DNA was extracted from cell monolayers and quantitative PCR was 
performed to assess 16S gene copy number. Data shown reflects a correction in the average 
bacterial copy number as each organism presents two copies of 16S gene.  Consequently, the 
obtained copy numbers were divided by two. Figures represent the mean ± SEM (n=3). Statistical 
significance was assessed by one-way ANOVA with Dunnett’s post-hoc test comparing peptide 
treated samples to the untreated control (0µg/ml). A p value of £ 0.05 was considered significant. 
(**p£0.01).  
 
 
C	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3.1.3   Exposure to LL-37, PG-1 or SMAP-29 increases Waddlia chondrophila 
infectivity 
 
To assess whether cathelicidins alter the infectivity of W. chondrophila, the bacteria were 
directly exposed to varying concentrations of LL-37, PG-1 and SMAP-29 for 1 hour prior 
to host cell infection. 24 hours post infection, host cell monolayers were fixed. The 
number of intracellular inclusions in each treatment was then quantified and represented. 
An increase in the number of inclusions was observed after exposure to cathelicidins, 
indicating a higher infectivity as a result of LL-37, PG-1 and SMAP-29 treatment (Figure 
12A, 12B and 12C). This statistically significant increase occurred at all concentrations 
of LL-37 and PG-1 although SMAP-29 did not induce significant increases at 
concentrations below 50µg/ml. 
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Figure 12. Average number of inclusions after cathelicidin incubation with Waddlia 
chondrophila prior to host cell infection. W. chondrophila was pre-incubated for 1 hour with 
different peptide concentrations prior addition to HEp2 cell monolayers for another 1 hour 
incubation. At 24 hours post infection, immunostaining and counting of the inclusions was 
performed using an inverted fluorescence microscope. Data represents the average number of 
inclusions per treatment ± SEM (n=3). Significance was determined by one-way ANOVA with 
Dunnett’s post-hoc test comparing peptide treated samples to the untreated control (0µg/ml). 
*p£0.05, **p£0.01, *** p≤0.001. 
 
 
3.1.4   Exposure to LL-37, PG-1 or SMAP-29 increases W. chondrophila replication 
 
Following the same approach as previously adopted with C. trachomatis, the effect of 
cathelicidin exposure on the replication of W. chondrophila was assessed. W. 
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chondrophila was directly exposed to varying concentrations of either LL-37, PG-1 or 
SMAP-29 peptides prior infection of host cells. Following infection, the bacterial 
ribosomal 16S gene copies were quantified by qPCR, and revealed an increase in bacterial 
replication in response to peptide treatments. (Figure 13A, 13B and 13C). A high 
variability in total bacterial infection numbers was observed in the peptide treated 
samples.  Exposure to LL-37 and scrambled LL-37 resulted in statistically significant 
increases in gene copy number at concentrations of 25µg/ml or higher (Figure 13A). 
Exposure to PG-1 also increased measurable 16S gene copy number in all treatments, 
although due to the variability of the measured gene copy numbers, this was not 
statistically significant.  SMAP-29 exposure also appears to induce an increase in gene 
copy number.  
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Figure 13. Average Chlamydiales 16S gene copy number after exposure of Waddlia 
chondrophila to cathelicidins prior to host cell infection. W. chondrophila was exposed for 1 
hour to varying peptide concentrations prior to infection of HEp2 cell monolayers for an 
additional 1 hour. After 24 hours, DNA was extracted from cell monolayers and quantitative PCR 
was performed to assess 16S copy number. Data shown reflects a correction in the average 
bacterial copy number as each organism presents two copies of 16S gene. Consequently, the 
obtained copy numbers were divided by two. Figures represent the mean ± SEM (n=3). Statistical 
analysis was performed by one-way ANOVA and Dunnett´s post-hoc test comparing Waddlia 
chondrophila treated samples to the untreated control (0µg/ml). *p£0.05, **p£0.01. 
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3.2   The effect of host cell exposure to cathelicidins on C. trachomatis and W. 
chondrophila infection 
 
3.2.1   Host cell exposure to LL-37, but not PG-1 or SMAP-29, alters subsequent C. 
trachomatis infectivity 
 
To assess whether cathelicidin pre-treatment of host cells alter infectivity of C. 
trachomatis, HEp2 cells were directly exposed to varying concentrations of LL-37, PG-
1 and SMAP-29 for 1 hour prior to C. trachomatis infection. Following infection and 
incubation, host cell monolayers were fixed and bacterial inclusions were then 
specifically stained and visualised inside the host cells. The number of intracellular 
inclusions in each treatment was then quantified and represented (Figure 14A, 14B and 
14C). The obtained number of inclusions per treatment for each cathelicidin, did not 
reveal a clear effect on C. trachomatis infectivity as the number of inclusions was similar 
among the different concentrations in each treatment. 
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Figure 14. Average number of inclusions after host cell exposure to cathelicidins prior to C. 
trachomatis infection. Host cells were incubated for 1 hour with a range of peptide concentrations 
prior to infection with C. trachomatis for an additional 1 hour. After 24 hours, specific 
immunostaining and counting of the inclusions was then performed. Data represents the average 
number of inclusions per treatment ± SEM (n=3). Significance was determined by one-way 
ANOVA with Dunnett’s post-hoc test comparing peptide treated samples to the untreated control 
(0µg/ml). A p value £0.05 was considered significant. 
 
 
 
3.2.2   Host cell exposure to LL-37, PG-1 or SMAP-29 does not alter C. trachomatis 
replication 
 
To study whether cathelicidin pre-treatment of host cells alters replication of C. 
trachomatis, HEp2 cells were directly exposed to varying concentrations of LL-37, PG-
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1 and SMAP-29 for 1 hour prior to C. trachomatis infection. Following infection and 
incubation, the bacterial ribosomal 16S gene copies were quantified by qPCR, and 
revealed a decrease in bacterial replication in treatments where bacteria were exposed to 
high concentrations of peptide (Figures 15A, 15B and 15C). While PG-1 and SMAP-29 
exposure only resulted in a moderate decrease in the bacterial gene copy number, the 
human cathelicidin LL-37 induced a significant decrease at the highest concentration 
(10µg/ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Average Chlamydiales 16S gene copy number after host cell exposure to 
cathelicidins prior to C. trachomatis infection. Host cells were incubated for 1 hour with a range 
of peptide concentrations prior to infection with C. trachomatis for an additional 1 hour. After 24 
hours, DNA was extracted from cell monolayers and quantitative PCR was performed to assess 
16S copy number. Data shown reflects a correction in the average bacterial copy number as each 
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organism presents two copies of 16S gene. Consequently, the obtained copy numbers were 
divided by two.  Each copy number corresponds to one organism and figures represent mean ± 
SEM (n=3). Statistical analysis was performed by one-way ANOVA with Dunnett’s post-hoc test 
comparing peptide treated samples to the untreated control (0µg/ml). *p£0.05. 
 
 
3.2.3   Host cell exposure to LL-37, PG-1 or SMAP-29 does not alter W. chondrophila 
infectivity 
 
To assess whether cathelicidin pre-treatment of host cells alters infectivity of W. 
chondrophila, HEp2 cells were directly exposed to varying concentrations of LL-37, PG-
1 and SMAP-29 for 1 hour prior to W. chondrophila infection. Following infection and 
incubation, host cell monolayers were fixed and bacterial inclusions were then 
specifically stained and visualised inside the host cells. The average number of inclusions 
revealed minor decreases in W. chondrophila infectivity, following LL-37 and PG-1 
exposure, but this was not statistically significant (Figures 16A and 16B).  SMAP-29 
exposure did not alter infectivity (Figure 16C). 
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Figure 16. Average number of inclusions after host cell exposure to cathelicidins prior to 
Waddlia chondrophila infection. HEp2 cell monolayers were exposed for 1 hour to various 
peptide concentrations prior to infection with Waddlia chondrophila for an additional 1 hour. 
After 24 hours, specific immunostaining and counting of the inclusions was performed using an 
inverted fluorescence microscope. Data represents the average number of inclusions counted per 
treatment ± SEM (n=3). Significance was determined by one-way ANOVA with Dunnett’s post-
hoc test comparing W. chondrophila treated samples to the untreated control (0µg/ml). A p value 
of £0.05 was considered significant. 
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3.2.4   Host cell exposure to LL-37, PG-1 or SMAP-29 does not alter W. chondrophila 
replication 
 
To study whether cathelicidin pre-treatment of host cells alters replication of W. 
chondrophila, HEp2 cells were directly exposed to varying concentrations of LL-37, PG-
1 and SMAP-29 for 1 hour prior to W. chondrophila infection. Following infection and 
incubation, the bacterial ribosomal 16S gene copies were quantified by qPCR. Host cell 
exposure to cathelicidins did not reveal a significant increase or decrease of W. 
chondrophila replication at the used concentrations of LL-37, PG-1 and SMAP-29 
(Figure 17A, 17B and 17C). A similar trend is seen in Figure 17A and 17B, where 
exposure to 5 µg/ml of PG-1 and LL-37 decreased moderately bacterial copy number. On 
the contrary, exposure to lower concentrations of SMAP-29 resulted in a similar copy 
number, being only the highest concentration the one that promoted a higher replication. 
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Figure 17. Average Chlamydiales 16S gene copy number after host cell exposure to 
cathelicidins prior to W. chondrophila infection. Host cells were pre-incubated for 1 hour with 
a range of peptide concentrations prior to infection for an additional 1 hour. After 24 hours, DNA 
was extracted from cell monolayers and qPCR was performed to assess 16S copy number. Data 
shown reflects a correction in the average bacterial copy number as each organism presents two 
copies of 16S gene. Consequently, the obtained copy numbers were divided by two. Figures 
represent mean ± SEM (n=3). Statistical significance was assessed by one-way ANOVA with 
Dunnett’s post-hoc test comparing peptide treated samples to the untreated control (0µg/ml). A p 
value of £ 0.05 was considered significant. 
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3.3   The effect of cathelicidin exposure on host cell death 
 
3.3.1   Exposure to LL-37, PG-1 and SMAP-29 does not induce necrosis in C. 
trachomatis infected host cells 
 
To determine if cathelicidin exposure induced host cell death in C. trachomatis infected 
HEp2 cells, supernatants were analysed for the presence of the intracellular enzyme 
lactate dehydrogenase, indicative of necrotic cell death. The supernatants analysed were 
obtained following direct cathelicidin treatment of C. trachomatis prior to host cell 
infection (Results section 1) and represented 24 hours post-infection. Supernatants were 
recovered 24 hours post infection with bacteria that had been directly exposed to peptides 
prior incubation with host cells. Only when C. trachomatis was exposed to 0µg/ml 
SMAP-29, the LDH release was significantly higher than when host cells were 
uninfected. Bacterial exposure to LL-37, PG-1 and SMAP-29 did not resulted in an 
increase of host cell death, even when bacteria was exposed to higher concentrations of 
peptides (Figure 18A, 18B and 18C). 
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Figure 18. Average LDH release from host cells following infection with C. trachomatis that 
had previously been exposed to cathelicidins.  C. trachomatis was exposed for 1 hour to 
different cathelicidin concentrations prior host cell infection for a further 1 hour. Following a 
wash step and 24 hours incubation, supernatants were collected and LDH release was determined 
using a CytoTox 96® Non-Radioactive Cytotoxicity kit. Results are shown as a mean ± SEM of 
three independent experiments. Statistical analysis was performed using one-way ANOVA with 
Dunnett multiple comparison test to compare each treatment to the infected untreated control 
(0µg/ml). A p value of £0.05 was considered significant. **p£0.01.  
 
 
 
3.3.2   Exposure to LL-37, PG-1 and SMAP-29 does not induce necrosis in W. 
chondrophila infected host cells 
 
To determine if cathelicidins induced host cell death in W. chondrophila infected HEp2 
cells, supernatants recovered after 24 hours incubation with W. chondrophila were 
analysed by CytoTox 96® Non-Radioactive Cytotoxicity kit to study the host cell LDH 
release (Figure 19A, 19B and 19C). Detectable LDH release was not higher in any of the 
analysed samples compared to the uninfected negative control, even at higher 
concentrations of cathelicidin. 
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Figure 19. Average LDH release from host cells following infection with W. chondrophila 
that had previously been exposed to cathelicidins. W. chondrophila was exposed for 1 hour to 
different cathelicidin concentrations prior to host cell infection for a further 1 hour incubation. 
Following a washing step and 24 hours incubation, supernatants were collected and LDH release 
was determined using a CytoTox 96® Non-Radioactive Cytotoxicity kit. Results are shown as a 
mean ± SEM of three independent experiments. Statistical analysis was performed using one-way 
ANOVA with Dunnett’s multiple comparison test to compare each treatment to the infected 
untreated control (0µg/ml). A p value of £0.05 was considered significant. 
 
 
 
3.4   The effect of cathelicidins on the host inflammatory response during C. 
trachomatis and W. chondrophila infection 
 
 
3.4.1   Modulation of IL-8 release by cathelicidins in uninfected host cells 
 
3.4.1.1  Exposure to LL-37, PG-1 and SMAP-29 does not alter IL-8 release by HEp2 
cells 
 
Cathelicidins have been shown to elicit a host response to infection partly through their 
ability to modulate immune and inflammatory responses. HEp2 cells were exposed to 
peptides at varying concentrations for 1 hour, then washed and incubated for 24 h. 
Supernatants were analysed by Enzyme-Linked Immunosorbent Assay (ELISA). No 
significant increase or decrease in the IL-8 production was found after LL-37, PG-1 and 
SMAP-29 exposure (Figure 20A, 20B and 20C) when compared to untreated cells.  
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Figure 20. IL-8 release (pg/ml) by HEp2 cells following exposure to cathelicidins. HEp2 host 
cells were exposed to different cathelicidin concentrations for 1 h. Following a wash step, cells 
were incubated for 24h at 37ºC.  Supernatants were collected and analysed, and results are shown 
as a mean ± SEM of three independent experiments. Significance was determined by one-way 
ANOVA with Dunnett’s post-hoc test to compare each treatment to the rest. A p value of £0.05 
was considered significant. 
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3.4.2   The effect of cathelicidins on IL-8 production in C. trachomatis infection 
 
3.4.2.1  Cathelicidins dramatically enhance IL-8 release by host cells during C. 
trachomatis infection 
 
C. trachomatis was exposed for 1h to various cathelicidin concentrations and incubated 
with the host cell for a further 1h. After a washing step and subsequent 24 h incubation, 
supernatants were recovered at 24 h and 48 h time points and analysed by ELISA to 
determine IL-8 release by host cells (Figures 21A-21F). At 24 h, there was an increase in 
IL-8 production by host cells in response to infection. When the bacteria were exposed to 
LL-37, PG-1 and SMAP-29, there was no significant alteration on IL-8 release compared 
to either the uninfected cells or the bacteria minus peptide treatments. However, at 48 h 
post infection, cathelicidin treatment of C. trachomatis promoted substantial IL-8 release 
by the host cells comparing to the non-peptide treated bacteria. LL-37 and SMAP-29 
induced a statistically significant increase in IL-8 production. PG-1 also induced an 
increase in the host IL-8 production though it was not significant. Results from C. 
trachomatis MOI 0.1 were very low and are shown in the Results Appendix 5.1.1. 
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Figure 21. IL-8 release (pg/ml) after C. trachomatis (MOI 1) exposure to cathelicidins. C. 
trachomatis (MOI 1) was exposed for 1 hour to different cathelicidin concentrations prior to host 
cell infection for a further 1 hour. After 24 hours and 48 hours incubation, supernatants were 
collected and analysed by ELISA using uninfected cells as control. Results are shown as a mean 
± SEM of three independent experiments. Statistical analysis was performed by one-way 
ANOVA with Dunnett’s post-hoc test to compare each treatment to the untreated infected control 
(0µg/ml). *p£0.05, ** p£0.01, *** p≤0.001. 
 
 
3.4.2.2  Host cell exposure to LL-37, PG-1 and SMAP-29 prior to C. trachomatis 
infection can alter IL-8 release 
 
HEp2 cells were exposed to peptides for 1 hour and then infected with C. trachomatis 
(MOI 0.1 and 1) for a further 1 hour. Supernatants were recovered at 24 and 48 h and 
analysed by ELISA. Host cell treatment with LL-37 or SMAP-29 did not alter IL-8 
production when compared to the infected control. However, when pre-exposing host 
cells to the porcine cathelicidin Protegrin-1, a reduction in IL-8 production by the host 
cells was observed at both peptide concentrations (Figures 22A, 22B and 22C). Results 
obtained from 24 h infection course of C. trachomatis MOI 0.1 can be found in the Results 
Appendix 5.1.2.	  	  
 
When host cells were infected with an MOI 1 of C. trachomatis IL-8 production was 
higher at 48 h post infection than 24 h post infection (Figure 23A-23F). Exposure to 
5µg/ml of PG-1 and SMAP-29 showed a moderate increase in the IL-8 production 
comparing to the untreated sample at 24 h p.i. whereas this increase was not statistically 
significant with exposure to the pathogen only. 
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Figure 22. IL-8 release (pg/ml) after host cell exposure to cathelicidins prior to infection 
(MOI 0.1). HEp2 cells were pre-incubated for 1 hour with various cathelicidin concentrations 
and then infected for a further 1 hour with C. trachomatis (MOI 0.1). After 48 hours incubation, 
supernatants were collected and analysed using uninfected cells as control. Results are shown as 
a mean ± SEM of three independent experiments. Statistical analysis was performed by one-way 
ANOVA with Dunnett’s post-hoc test to compare each treatment to the infected control (0µg/ml). 
*p£0.05, ** p£0.01, **** p≤0.0001. 
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Figure 23. IL-8 release (pg/ml) after host cell exposure to cathelicidins prior to infection 
with C. trachomatis (MOI 1).  HEp2 cells were incubated for 1 hour with various cathelicidin 
concentrations and then infected for a further 1 hour with C. trachomatis. After 24 hours and 48 
hours incubation, supernatants were collected and analysed using infected cells without peptide 
treatment as a control. Results are shown as a mean ± SEM of three independent experiments. 
Statistical analysis was performed by one-way ANOVA with Dunnett’s post-hoc test to compare 
each treatment to the infected control. * p<0.05, ***p<0.001, **** p<0.0001. 
 
 
3.4.3   The effect of cathelicidins on IL-8 production in W. chondrophila infection 
 
The effect of cathelicidins was also subjected to study in Waddlia chondrophila infection. 
As its infection cycle is shorter, the 24 h time point was enough to build an idea of the 
effects of the different treatments on the host cell inflammatory response through IL-8 
production. 
 
3.4.3.1  LL-37, PG-1 and SMAP-29 exposure alters W. chondrophila induced IL-8 
production in epithelial host cells 
 
W. chondrophila (MOI 0.1 and 1) was exposed for 1h to either LL-37, SMAP-29 or 
Protegrin-1 and the mix was added to HEp2 for a further 1 hour incubation. After a further 
24 hours incubation, supernatants were recovered and analysed by ELISA (Figure 24A-
24F). As expected, IL-8 production in response to W. chondrophila was observed to be 
higher at MOI 1 than at MOI 0.1. However, it was noted that IL-8 production was 
substantially higher when W. chondrophila had been pre-treated with cathelicidin, 
compared to infected control. This observation was only noted to be statistically 
significant when an MOI of 1 was utilized (Figures 24B, Figure 24D and Figure 24F).   
At MOI 1 a significant difference between IL-8 production is seen when W. chondrophila 
has been exposed to cathelicidins than in the untreated bacteria. This difference is higher 
when W. chondrophila (MOI 1) was exposed to 50µg/ml and 100µg/ml of PG-1 and to 
50µg/ml of LL-37. 
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Figure 24. IL-8 release (pg/ml) after W. chondrophila exposure to cathelicidins. W. 
chondrophila (MOI 0.1 and 1) was exposed for 1 hour to different cathelicidin concentrations 
prior host cell infection for a further 1 hour. After 24 hours incubation, supernatants were 
collected and analysed by ELISA using uninfected cells as control. Results are shown as a mean 
± SEM of three independent experiments. Statistical analysis was performed by one-way 
ANOVA with Dunnett’s post-hoc test to compare each treatment to the infected control sample. 
*p£0.05, ** p£0.01. 
 
 
3.4.3.2  Host cell exposure to LL-37, PG-1 and SMAP-29 prior to W. chondrophila 
infection does not alter IL-8 production 
 
HEp2 cells were exposed to cathelicidins for 1 hour and then infected with W. 
chondrophila (MOI 0.1 and 1) for a further 1 h. Supernatants were recovered at 24 hours 
post infection and were analysed by ELISA. Cathelicidin pre-treatment of the host cell 
did not appear to mediate any alteration in the IL-8 response of the host cell to infection 
(Figure25A-25F). Host cell exposure to cathelicidins prior to infection resulted in a higher 
IL-8 released than when the bacteria was directly exposed to the peptides (Figure 24). 
Host cell pre-treatment did not result in a differential IL-8 production comparing to the 
untreated control, contrary to when the bacteria was exposed to different cathelicidin 
concentrations, which resulted in a higher IL-8 production than the infected control. 
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Figure 25. IL-8 release (pg/ml) after host cell exposure to cathelicidins prior to infection 
with W. chondrophila.  HEp2 cells were incubated for 1 hour with various cathelicidin 
concentrations and then infected for a further 1 hour with W. chondrophila (MOI 0.1 and 1). After 
24 hours incubation, supernatants were collected and analysed using infected cells without 
peptide treatment as a control. Results are shown as a mean ± SEM of three independent 
experiments. Statistical analysis was performed by one-way ANOVA with Dunnett’s post-hoc 
test to compare each treatment to the infected control. * p£0.05, **p£0.01, *** p£0.001. 
 
 
 
3.5   Intracellular localisation of Dansyl-labelled LL-37 
 
3.5.1   dLL-37 can enter the host cell 
 
To determine if LL-37 is internalised and retained by the host cell, HEp2 cells were 
exposed to dansyl-labelled-LL-37 for 1 hour, fixed and stained with mounting medium 
containing DAPI. Slides were imaged by confocal microscopy (Figure 26). The images 
confirmed the presence of LL-37 in the cytoplasm of the cell at this time point. To avoid 
conflicting detection due to overlapping of the excitation and emission spectrum of both 
fluorophores: dLL-37 λex 338nm, λem 500nm, DAPI (λex 360nm, λem 460nm), cells were 
also treated with dansyl-LL-37 and a mounting media without DAPI was used (). Imaging 
by confocal microscopy revealed an extra-nuclear presence of dLL-37 inside HEp2 cells. 
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Figure 26. Dansyl-LL-37 localisation within HEp2 cells counterstained with DAPI. HEp2 
cells were treated with dansyl-LL-37 (10µg/ml) for 1 hour at 37 ºC. Cells were fixed and DAPI 
stain was added before imaging by confocal microscopy. A merged DAPI/ dansyl-LL-37 (E, F) 
images are shown, nuclei in blue (C, D) and dansyl-labelled LL-37 in green (A, B). 
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Figure 27. Dansyl-LL-37 localisation within HEp2 cells. HEp2 cells were treated with dansyl-
LL-37, 10µg/ml (A) and 30µg/ml (B) for 1 hour at 37 ºC. Cells were fixed and the slides were 
mounted in mounting media without DAPI prior imaging by confocal microscopy. 
 
 
3.5.2   Dansyl-LL-37 co-localizes with the intracellular bacterial inclusions 
 
In order to determine if infection alters intracellular LL-37 localisation, HEp2 cells were 
infected for 1 h with C. trachomatis or W. chondrophila. (MOI 1). Media containing 
extracellular bacteria was then removed and fresh culture media was added. After a 
further 23 hours of incubation, cells were exposed to 10µg/ml of dansyl LL-37 for 1 hour. 
Cells were then washed and fixed with acetone prior to imaging by confocal microscopy. 
LL-37 appeared to colocalize with Waddlia chondrophila inclusions, as indicated by 
orange staining, but not with C. trachomatis inclusions (Figure 28). 
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Figure 28. Dansyl-labelled-LL-37 treatment of HEp2 infected cells (G, H and I). HEp2 cells 
were treated with dansyl-LL-37, 10µg/ml for 1 hour at 37 ºC. Cells were fixed and the slides were 
mounted prior imaging by confocal microscopy. C. trachomatis and W. chondrophila are seen in 
red (B and C respectively), dLL-37 is seen in green (D, E and F).  
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4  Discussion  
 
 
4.1   The direct antimicrobial effects of cathelicidins on C. trachomatis and W. 
chondrophila 
 
Cathelicidins have demonstrated powerful antibacterial and antiviral activity as well as 
immunomodulatory properties (Kościuczuk et al., 2012; Barlow et al., 2014). Knowing 
the potential of cathelicidins against intracellular pathogens, we have chosen three 
cathelicidins: human LL-37, porcine PG-1 and ovine SMAP-29 for comparative analysis 
of their antimicrobial activity against Waddlia chondrophila and Chlamydia trachomatis. 
In this study, the direct antimicrobial effect of cathelicidins on C. trachomatis and W. 
chondrophila was studied. For both pathogens, changes in replication and infectivity were 
studied as endpoints to determine the protective and therapeutic efficacy of cathelicidins 
against these infections.  
 
Only a limited number of studies have been published which have studied chlamydial 
responses to CHDP, with the primary focus being on cathelicidins and defensins (Yasin 
et al., 1996; Chong-Cerrillo et al., 2003; Donati et al., 2005). Most of the studies that 
have been performed so far were focused on members of the Chlamydiaceae family, 
leaving other families of the Chlamydiae phylum behind. Very little is known about the 
effect of cathelicidins on Waddlia chondrophila infection. Coyle et al., demonstrated that 
in response to W. chondrophila infection of ovine AH-1 trophoblasts, ovine defensins 
expression was upregulated, though no upregulation of the ovine cathelicidin SMAP-29 
was observed, as only constitutive levels were found to be expressed (Coyle et al., 2016).  
Donati et al. also studied the activity of different cathelicidins against Simkania 
negevensis, a Gram-negative bacterium belonging to the family of Simkaniaceae in the 
order Chlamydiales. S. negevensis was not found to be sensitive to LL-37, even at very 
high concentrations of the peptide (80µg/ml). On the contrary, it was found to be 
susceptible to PG-1 and SMAP-29 at very low concentrations (1 to 0.1µg/mL). 
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4.1.1   Exposure of Chlamydia trachomatis to LL-37, PG-1 or SMAP-29 prior to host 
cell infection reduces replication and infectivity 
 
In this study, Chlamydia trachomatis L2 was directly exposed to cathelicidins prior to the 
addition of the pathogen to host cells, and pathogen replication was found to be affected. 
Replication was decreased after cathelicidin exposure, with SMAP-29 being the most 
effective peptide. The potent antimicrobial activity of SMAP-29 has been previously 
observed against various pathogens. In the study of different direct cathelicidin treatments 
against clinical strains of P. aeruginosa, SMAP-29 was found to be the most effective 
cathelicidin in preventing bacterial growth (Saiman et al., 2001). SMAP-29 also resulted 
the most effective cathelicidin against other bacterial species, including S. aureus and E. 
coli, as it prevented its growth at lower peptide concentrations and showed a broad 
spectrum activity (Skerlavaj et al., 1999). 
 
Infectivity, as measured by a significant decrease in chlamydial inclusions, was also 
decreased by all cathelicidins used in this study, with 50µg/ml being the most effective 
concentration for all peptides (Figure 12).  These results support the findings obtained in 
previous studies of C. trachomatis responses to cathelicidin exposure that resulted in 
infectivity reductions. Other studies have shown that when different C. trachomatis 
serovars were exposed to PG-1, the number of inclusion-forming units (IFU), which is 
directly equivalent to the number of inclusions, was highly reduced (Yasin et al., 1996; 
Chong-Cerrillo et al., 2003). This decrease was more potent than when C. trachomatis 
was exposed to defensins. L2 was found to be the most susceptible serovar to PG-1 and 
other tested antimicrobial peptides when compared to serovars E and H (Chong-Cerrillo 
et al., 2003). The susceptibility to PG-1 was also noted by Donati et al., though this was 
at substantially higher concentrations (80µg/ml ± 1.4µg/ml). The most effective 
antimicrobial activity was found by when C. trachomatis was exposed to SMAP-29, as it 
was determined that there was a 50% drop in infectivity at a concentration of 10µg/ml 
(Donati et al., 2005). Other Chlamydia species have shown more susceptibility to SMAP-
29 than to PG-1 regarding infectivity. This is the case in the context of Chlamydia suis 
(Donati et al., 2007) and Chlamydia pneumoniae exposure (Donati et al., 2005).  
 
Our findings confirmed an antimicrobial effect of cathelicidins in C. trachomatis 
infection models. However, differences between studies in the effectiveness of the 
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peptides may be attributed to the host cell model used in the experiments performed by 
Donati et al., and Yasin et al., which were animal host cell models. In contrast, all the 
experimental work in our study used a human host cell model. Another important 
difference between previous studies and the methodology followed in this work is the 
composition of the solutions in which the peptides were dissolved. Host defence peptides 
are known to exhibit salt sensitivity to high salt conditions, such as those found in PBS, 
which can affect their antimicrobial activity.  In addition, serum has also been shown to 
inhibit cathelicidin activity (Travis et al., 2000; Dürr, Sudheendra and Ramamoorthy, 
2006). With these considerations, this work was conducted using physiological 
conditions in all the experiments, whereby peptides and bacteria were diluted and 
incubated in serum-free host cell culture media (IMDM) to allow cathelicidins the best 
possible chance to exhibit inhibitory effects. This contrasts with the experimental 
approach employed by Donati et al., who used stock peptide solutions made with PBS, 
further diluted in SPG buffer (composed of sodium phosphate, sucrose and glutamic acid) 
for the incubation with bacteria. Yasin et al., also used a similar buffer in their 
experiments.  
 
The data obtained in this work points to cathelicidins exerting inhibitory effects in the 
context of both pathogen replication and in infectivity, although they appear to be more 
effective at altering infectivity. While cathelicidin treatment of C. trachomatis had an 
impact on host cell infection, it would be anticipated that the functional consequence of 
this would be that less elementary bodies would enter the host cell, differentiate and 
multiply. This is likely due to the direct antimicrobial effect as previously described, 
mediated by bacterial membrane permeabilisation and the consequent death of the 
organisms (Dawson and Liu, 2009; Bolintineanu and Kaznessis, 2011). 
 
 
4.1.2   Exposure of W. chondrophila to LL-37, PG-1 or SMAP-29 increases replication 
and infectivity 
 
In contrast to the inhibition of infectivity and replication of C. trachomatis by 
cathelicidins, direct exposure of W. chondrophila to cathelicidins prior to the addition of 
the pathogen to host cells induced an increase in replication and infectivity. The lowest 
concentrations of LL-37 and PG-1 (10µg/ml) were sufficient to observe significant 
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increases in Waddlia infectivity (Figure 13). As W. chondrophila has only relatively 
recently been characterised, there is a paucity of research in terms of its susceptibility to 
antimicrobial treatments, in particular HDPs. Our results suggest that cathelicidins have 
species specific effects towards chlamydial pathogens, and that W. chondrophila does not 
demonstrate any sensitivity to these peptides. This observation was relatively unexpected, 
as resistance to antimicrobial peptides has only been previously described in certain 
Gram-negative bacteria. For example, Staphylococcus aureus can secrete a protein 
(Staphylokinase) that can interact with and neutralize α-defensins (Jin et al., 2004), and 
E. coli can produce an outer membrane protease, OmpT that can protect the bacteria by 
mediating the proteolytic degradation of LL-­‐37 (Thomassin et al., 2012). In mCRAMP 
(LL-37 orthologue) knockout mice, E. coli was found to be less infective than in wild-
type mice (Danka and Hunstad, 2015), which holds some similarity with what has been 
observed with Waddlia in this study.  
 
Other resistance mechanisms employed by bacteria involve net cell surface charge 
alteration, peptide efflux from the bacterial cytoplasm to the extracellular space, 
restriction of antimicrobial peptide access to their targets and proteolytic cleavage of the 
peptides (Cole and Nizet, 2016). W. chondrophila is not only resistant to the direct 
antimicrobial activity of all cathelicidins tested, but also appears to thrive in its presence. 
In contrast to what was observed with W. chondrophila, cathelicidin peptides have shown 
substantial in vitro activity against C. trachomatis, C. pneumoniae and Simkania 
nevegensis. However, some animal Chlamydiae, including Chlamydia abortus, 
Chlamydia psitacci and Chlamydia felis, were not particularly sensitive to cathelicidins 
even at very high concentrations (>80µg/ml)(Donati et al., 2005) although this may be 
attributable to the experimental conditions as previously discussed. 
 
In the context of the involved mechanisms, charge may play a role. The three peptides 
used in this study have different net charges, with SMAP-29 displaying the most cationic 
(net charge +10) and LL-37 and PG-1 less cationic (both with net charge +6). Increased 
cationic charge is associated with increased antimicrobial activity against Gram-negative 
and Gram-positive bacteria (Travis et al., 2000; Sorensen and Borregaard, 2005; Dawson 
and Liu, 2009). We would suggest that other mechanisms must be involved, as the data 
obtained from cathelicidin treatment of C. trachomatis shows that not only SMAP-29 is 
one of the most effective reducing replication and infectivity, but also PG-1. Data 
	  
82 
obtained from LL-37 and PG-1 treatments of W. chondrophila indicates more substantial 
increases in replication and infectivity in response to these peptide treatments, which 
joined to C. trachomatis results, could suggest that the charge of this peptides might not 
be key for the peptide effect on these pathogens. It may be possible that other peptide 
variables, such as peptide sequences, might play a role.  
 
 
4.2   The effect of host cell exposure to cathelicidins on C. trachomatis and W. 
chondrophila infection 
 
In addition to the direct antimicrobial effect of cathelicidins, we also examined the 
potential for cathelicidins to alter the host pathogen response by direct treatment of the 
host cell. In this context, host cells were exposed to the peptides prior to infection and 
effect on bacterial infectivity and replication was then assessed as before. The cathelicidin 
concentrations used in this set of experiments were identical to the peptide concentrations 
that the host cells were exposed to after direct pathogen-peptide exposure.  
 
 
4.2.1   Host cell exposure to LL-37, but not PG-1 or SMAP-29, alters subsequent C. 
trachomatis replication  
 
When host cells were exposed to cathelicidins prior to infection, C. trachomatis 
infectivity was unaltered (Figure 15). In contrast, host cell pre-treatment with LL-37 
apparently reduced C. trachomatis replication due to a decrease in the copy number 
detected by qPCR (Figure 14). Most studies performed with cathelicidins have focused 
upon the direct antimicrobial properties of the peptides against different pathogens, and 
host cell exposure to peptides have been studied to much a lower extent, though the 
immunomodulatory role of cathelicidins is well known.  LL-37 can induce the production 
of several chemokines, though there is some debate as to whether this is achieved by 
direct chemotaxis induction or it happens indirectly by induction of classical chemokines 
(Shafer, 2006). LL-37 can up-regulate receptors which a broad range of ligands such as 
chemokines, interleukins and hormones. These effects displayed by LL-37 may 
contribute to the protective effect that we observed after LL-37 treatment of host cells 
prior to C. trachomatis infection. Again, the fact that the host cell line used in all our 
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studies was human derived may be one of the factors to explain why LL-37, the sole 
human cathelicidin, was particularly effective in reducing bacterial replication.  The 
observation that replication and not infectivity has been altered also support the 
hypothesis that pathogen adhesion and entry is not altered by host cell pre-treatment.  
 
Previous studies have also found that cathelicidins might hold potential as prophylactic 
treatments against infection. For example, in an animal model, Schneider et al., showed 
that prophylactic treatment of zebrafish embryos with the chicken cathelicidin, CATH-2, 
led to a partial protection against lethal bacterial infections, such as those caused by 
Salmonella (Schneider et al., 2016). In models of hepatitis C viral infection, LL-37 was 
also observed to have a key protective effect as host cells pre-treatment with LL-37 
attenuated virus infectivity (Matsumura et al., 2016). Other studies have aimed to 
investigate if cathelicidin pre-treatment of host cells could trigger host cell responses that 
would lead to differential effects post infection.  
 
In our study, the mechanisms involved in the LL-37 mediated reduction in bacterial 
replication are not fully understood. We hypothesised that cathelicidin treatment could 
provoke an inflammatory state in the host cells which would attenuate C. trachomatis 
infection. This should therefore be the subject of additional work to perform a full 
characterization of the processes involved. 
 
 
4.2.2   Host cell exposure to LL-37, PG-1 or SMAP-29 does not alter W. chondrophila 
replication and infectivity 
 
In our study, when host cells were exposed to cathelicidins prior to infection, W. 
chondrophila infectivity and replication were unaltered. This suggests that any host-cell 
based mechanism by which LL-37 reduced C. trachomatis replication was not effective 
in W. chondrophila. However, in contrast to our observations with C. trachomatis, W. 
chondrophila was resistant to the antimicrobial properties of the peptides, and this could 
therefore be a factor in this observation.  We could hypothesize that a direct interaction 
occurs between peptide and bacteria that favours enhanced bacterial adhesion and 
internalization, although this requires further experimental study.  
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In addition, differences between this two pathogens could be key in their opposing 
responses to host-cell treatment with the peptide. The chlamydial outer membrane, which 
is crucial for adhesion and invasion, is comprised of several different proteins between 
species. Many proteins of the outer membrane complex (OMC) of the Chlamydiaceae 
family, such as porin B and polymorphic outer membrane proteins (Pmps), have no 
homologues in Waddlia. Further studies could focus upon elucidating a role for these 
proteins in susceptibility to cathelicidin exposure. 
 
Furthermore, despite growing in a variety of human cell lines, W. chondrophila lacks 
some features associated with C. trachomatis infection, such as inhibition of apoptosis 
(Dille et al., 2015). Given the established relationship between host defence peptides and 
modulation of cell death pathways, this was an area of interest for us in terms of 
elucidating the exact underlying mechanisms in our observations and is discussed below.  
 
 
  
4.3   The effect of cathelicidins exposure on host cell death  
 
The direct antimicrobial activity of cathelicidins has been shown to involve interactions 
with the pathogen membrane and subsequent permeabilisation (Dawson and Liu, 2009; 
Bolintineanu and Kaznessis, 2011). It has been observed that CHDP preferentially 
permeabilize prokaryotic membranes, although the mechanisms of membrane 
discrimination, between the pathogen and the host cell membranes, is still not fully 
understood (Chen et al., 2007). Chen et al., suggested that peptide specificity between 
eukaryotic and prokaryotic cells depends upon the compositional difference in the lipids 
between the two types of membranes.  
 
It has been well established that high concentrations of cathelicidins can promote host 
cell death by necrosis. SMAP-29 has been found to be the most cytotoxic compared to 
other ovine cathelicidins used, reducing the viability of a number of different cell lines 
by 50% from 50-100µg/ml concentrations (Jacob et al., 2014). Similarly, the in vitro 
cytotoxicity of LL-37 was studied in A549 cells and concentrations lower than 50µg/ml 
of the peptide were found not induce to host cell death (Gordon et al., 2005). A strong 
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relationship between dose- and time-dependent cytotoxic activity was found in HepG2 
cells after PG-1 exposure (Niu et al., 2015).  
 
Although the cytotoxicity of cathelicidins is variable among host cell lines and depends 
upon the dosage and time of exposure, the concentrations used in our experiments did not 
promote host cell death. These results confirmed our predictions about using a safe range 
of cathelicidins that will not promote host cell death but will have an impact on the 
pathogens. To establish if the peptide concentrations used in this study promoted host 
(HEp2) cell death during infection, cytosolic lactate dehydrogenase release (LDH) was 
studied as an indicator of plasma membrane disruption. It was found that, when cells were 
exposed for 1 hour to both cathelicidins and bacteria, there was no significant increase in 
LDH release into the supernatant in comparison to the untreated controls (Figure 18 and 
19). Infection with Waddlia chondrophila alone also did not lead to an increased LDH 
release increase. However, in C. trachomatis infection and SMAP-29 treatment, the LDH 
release was higher than the uninfected control though the percentage of total LDH release 
was still relatively low (£15% total LDH release). Given that SMAP-29 has previously 
been shown to be one of the most cytotoxic cathelicidins in the context of mammalian 
cells, this observation is interesting as it indicates that induction of host cell death is 
unlikely to be the mechanism for reductions observed in bacterial replication.  
 
Previous studies have observed increased LDH release and cytotoxicity mediated by 
cathelicidins in the context of other pathogens. Sousa et al., observed a reduction in host 
cell metabolic activity during HRV infection and exposure to ≥20µg/ml LL-37, although 
there was not significant increase in LDH release at the concentrations of LL-37 tested. 
However, in healthy cells, exposure to a superphysiological concentration (100µg/ml) of 
LL-37 for 6 hours did induce a significant increase in LDH released from cells, suggesting 
a time-dependent cytotoxic effect only at the highest concentration (Sousa et al., 2017). 
Notably, in influenza A virus-infected neutrophils that were exposed to LL-37, a 
significant increase in LDH release was not observed at peptide concentrations lower than 
15µg/ml (Tripathi et al., 2014). In the transformed bronchial epithelial cell line, 
16HBE14o- the induction of host cell death by apoptosis after LL-37 treatment and P. 
aeruginosa infection was studied (Barlow et al., 2010). It was shown that only when both 
bacteria and peptide were added to the cells, apoptosis was significantly increased at 
lower peptide concentrations.  
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In summary, our results indicate that the cathelicidin concentrations used in this study 
were not cytotoxic towards HEp2 cells via the induction of necrosis at the time points 
studied. This would suggest that induction of host necrotic cell death by cathelicidins was 
not a mechanism by which LL-37, or indeed the other cathelicidins used, were exerting 
indirect antimicrobial effects towards C. trachomatis.  
 
 
 
4.4   The effect of cathelicidins on the host cell inflammatory response during 
C. trachomatis and W. chondrophila infection 
 
Disease and pathology caused by Chlamydia infection can be a result of sustained 
inflammation-associated tissue damage (Beatty, Byrne and Morrison, 1994; Darville and 
Hiltke, 2010). The pro-inflammatory cytokine, Interleukin-8 (IL-8), has been shown to 
be produced by cells in response to C. trachomatis infection (Rasmussen et al., 1997).  
Due to the broad immunomodulatory activities of cathelicidins (Turner et al., 1998; 
Kościuczuk et al., 2012; Barlow et al., 2014), we studied the inflammomodulatory effect 
of the peptides in the host cell response to chlamydial infection. To elucidate if the 
peptides alone were sufficient to elicit an inflammatory response, HEp2 cells were treated 
with cathelicidins and IL-8 release by these cells was quantified. Our data revealed that 
the IL-8 release by these cells in response to cathelicidin treatment was relatively low 
(<40pg/ml) and was not significantly different from the untreated control (Figure 20).  
 
Previous work in other cell lines, such as keratinocytes, has revealed that LL-37 promoted 
IL-8 production at concentrations higher than 13µg/ml (Braff et al., 2005), in neutrophils 
in a dose- and time-dependent manner at concentrations between 10-40µg/ml (Zheng et 
al., 2007) and in human airway smooth muscle cells at 10µg/ml (Zuyderduyn et al., 2006). 
The effect of LL-37 on chemokine induction in the human epithelial cell line A549 was 
studied confirming the ability of this peptide to promote a significant increase in the IL-
8 production at concentrations higher than 20µg/ml (Scott et al., 2002; Mookherjee et al., 
2006).  
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4.4.1   Cathelicidins enhance IL-8 release by host cells during C. trachomatis infection 
 
C. trachomatis was exposed to a range of cathelicidin concentrations, and the exposed 
bacteria subsequently used to infect HEp2 cells.  IL-8 release from the cells was measured 
by ELISA. It was found that exposure of C. trachomatis to cathelicidins prior to infection 
dramatically enhanced IL-8 release by the host cell.  This was observed 48h after 
infection, and LL-37 was found to be most effective at altering IL-8 release (Figure 21) 
compared to the other peptides. It has been shown that IL-8 is produced by C. trachomatis 
infected epithelial cells in a bacterial growth-dependent manner (Buchholz and Stephens, 
2006). In this model, we observed that the enhanced IL-8 release took place in the context 
of reduced bacterial infectivity and a reduction in the number of C. trachomatis infected 
cells.  
 
Dose dependent IL-8 release induced by cathelicidin treatment and in the presence of 
bacterial components, such as LPS, has been previously studied in neutrophils. When 
LPS was exposed to cell in the presence of LL-37, it was found that IL-8 release was 
decreased (Alalwani et al., 2010). The same effect was also observed when whole 
inactivated Gram- and Gram+ bacteria were used. In the epithelial line, A549 the same 
observation was recorded, confirming a role of LL-37 in reducing bacterial stimulation 
of inflammatory mediators (Scott et al., 2002). Interestingly, Scott et al. also observed 
that at higher concentrations of LL-37 (50–100µg/ml), the stimulation of IL-8 production 
independent of LPS occurred. Concentrations below 50µg/ml were shown to bind to 
bacterial components, like LPS, preventing its interaction with host cell receptors, such 
as TLR4, and reducing the inflammatory response (Scott et al., 2000, 2002). 
 
In our study, when host cells were exposed to cathelicidins prior to infection, IL-8 release 
was not altered compared to the negative control.  This may be due to the low, 
physiologically relevant concentrations of cathelicidins used in this study. It would be 
interesting to test higher, superphysiological peptide concentrations (>30µg/ml) to assess 
IL-8 release in HEp2 cells and compare them to cell lines tested in other published studies. 
PG-1 treatment resulted in a decrease in the IL-8 release, but again, it would be interesting 
to see the IL-8 production at higher PG-1 concentrations.  
 
	  
88 
Furthermore, we note that our studies have only focused on one cytokine, but we must 
consider the role of other cytokines in the inflammatory response to infection. Chlamydia 
infection induces the secretion of interleukin-1a (IL-1a), IL-1β, IL-6, IL-8, IL-18 and 
tumour necrosis factor alpha (TNF-α), among others (Rasmussen et al., 1997; Gervassi 
et al., 2004). Thus, to understand how the inflammatory response is being regulated by 
cathelicidins, it would be necessary to study the expression of other cytokines in the 
future. For example, IL-1a would be an ideal candidate as it is well known how this 
cytokine contributes to chlamydial induction of IL-8 production (Cheng et al., 2008). 
Cheng et al., found that cells expressing IL-1a, like HEp2 cells, significantly increased 
their production of IL-1a, IL-6, and IL-8 proteins after chlamydial infection. When the 
IL-1a receptor was blocked and the IL-1a was neutralised by antibodies, no decrease in 
the IL-8 production was seen at early stages and only a partial reduction was seen in later 
stages. That supports the hypothesis that different pathways independent of IL-1a must 
exists. Other studies also characterised the ability of IL-1 to induce IL-8 production by 
the host cell. In fallopian tube samples, it was observed that the use of an IL-1 receptor 
antagonist could avoid destructive effects of C. trachomatis infection by reducing the host 
cell inflammatory response (Hvid et al., 2007).  
 
Again, it is necessary to consider the variability among different cell lines and peptide 
dosage. It is possible that if we had used higher peptide concentrations in our studies we 
would have observed significant IL-8 production by HEp2 as had been previously shown 
in other cell lines. In the context of our study, increased IL-8 release in the presence of 
cathelicidins could be a result of enhanced PAMP release, due to pathogen death, and 
recognition by the host cells, although this would require further investigation.  
 
 
4.4.2   Host cell IL-8 production is only altered after W. chondrophila exposure to LL-
37, PG-1 and SMAP-29  
 
The Waddlia chondrophila infective cycle is shorter than C. trachomatis. In contrast to 
C. trachomatis, all direct peptide treatments of W. chondrophila prior to infection resulted 
in significant increases in IL-8 production. The most significant effect was seen with use 
of the highest bacterial load (MOI 1). This may therefore be linked to the increased 
growth of the pathogen that can elicit a higher IL-8 release, which was comparable with 
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results previously shown by Wheelhouse et al. (Wheelhouse et al., 2014). The same 
pattern is seen in our study when C. trachomatis was directly exposed to peptides, 
although both pathogens differed substantially regarding replication and infectivity. We 
previously noted that peptide and bacteria incubation may have induced bacterial death, 
potentially releasing bacterial PAMPs that could increase the inflammatory response in 
C. trachomatis. However, the opposing response in W. chondrophila suggests that other 
variables are implicated.  
 
We would suggest that the increase in the pathogen number due to the peptide treatment 
could be promoting an enhanced inflammatory response. This hypothesis is supported by 
other studies which have observed that IL-8 is significantly increased in late stages of 
chlamydial infection and when the pathogen numbers were higher (Rasmussen et al., 
1997; Buchholz and Stephens, 2006; Cheng et al., 2008).  
In our study, host cell exposure to cathelicidin peptides did not produce an altered IL-8 
response when compared to the untreated control. In addition, when host cells were pre-
treated with peptides, infectivity and replication was not affected in W. chondrophila 
infection. While higher peptide concentrations may influence this, it must be considered 
how very high concentrations of the peptides might be toxic. Assessing how cathelicidins 
modulate the expression of other key cytokines and the possible impact on host cell 
membrane receptors is also a key area which requires further work. For this purpose, it 
might be necessary to consider other host cells, as HEp2 cells are known to lack functional 
TLR4 receptors on the membranes. As the lack of functional TLR4 does not affect 
Chlamydia adhesion and entry, this supports HEp2 cells as an adequate model for all the 
experiments performed in this work. However, comparable studies in other cells with 
functional TLR responses would help elucidate the mechanisms underlying the 
inflammatory response to this pathogen. 
 
As it has been mentioned previously, chlamydial infection induces the secretion of several 
cytokines by the host cell, including IL-1. This cytokine can increase IL-8 production 
during late stages of chlamydial infection. However, the role of IL-1a has not been as 
extensively studied in Waddlia as in Chlamydia infection. The comparative study of the 
expression of this cytokine in both pathogens might show a differential response. When 
the ovine trophoblast cell line AH-1 was infected with Waddlia, an analysis of the 
subsequent cytokine production was performed, including assessment of IL-8 and IL-1 
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(Coyle et al., 2016). An increase in the IL-8 response and in IL-1b was found, although 
the IL-8 increase was much more substantial. In contrast, IL-1a production was not 
increased significantly, even at a very high MOI (10). 
 
 
 
4.5  Intracellular localisation of Dansyl-labelled LL-37 
 
Our results indicated that cathelicidins mediated differential effects on C. trachomatis 
and W. chondrophila infectivity and replication, and thus we examined entry and 
localisation of the peptides in the host cell. Host cells were grown and infected with 
bacteria for 24 hours, and subsequently treated with fluorescently labelled LL-37. We 
observed that when healthy cells were treated with dansyl-labelled LL-37 for 1 hour, a 
predominantly cytoplasmic distribution in the host cells was observed. Interestingly, 
when cells were infected with the two pathogens and subsequently treated with dansyl-
labelled LL-37 for one hour, peptide distribution within the cell appeared to be altered, 
with more nuclear distribution compared to the uninfected control. Dansyl-LL-37 
localisation without infection (Figure 27) and the uninfected controls of dansyl-LL-37 
treatment (Figure 28) should exhibit similar peptide distributions, as the treatment was 
the same. The fact that they exhibit differential peptide distributions might point that the 
Figure 27 immunostaining might be artefactual. We also observed that some 
colocalisation of dansyl-LL-37 and bacteria occurred in Waddlia chondrophila infection. 
We did not observe colocalisation between C. trachomatis and dansyl-LL-37, and this 
may be due to the life cycle stage, which might make necessary to repeat the experiment 
with a longer Chlamydia incubation.  Our data provides tentative indications that the 
peptide could be colocalising with Waddlia inside the host cell, but this represents a 
potential avenue for further investigation.  
 
 Several studies have also looked at cathelicidin distribution in the host cell during 
infection. After 24 hours E. coli infection, Braff et al. found colocalisation between 
endogenous LL-37 and E. coli, thus pointing to the potential contribution of keratinocytes 
to cutaneous defence. In other studies utilising LL-37 immunostaining, it was shown that 
macrophages surrounded by high levels of LL-37 at infectious or inflammatory sites can 
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internalize cathelicidin to acquire higher bacterial killing activity (Tang et al., 2015). This 
study also found that the internalized LL-37 phagocytosed bacteria colocalised in 
endosomal and lysosomal compartments, which suggested that LL-37 may target and 
eliminate pathogens directly in these compartments. In our studies, the treatment regimen 
involved the addition of LL-37 after 24 hours of infection, whereas in other studies it has 
been added prior to infection. While our approach examined cathelicidin localisation in 
an established infection, alternative treatment approaches would also be of value.   
 
 
 
4.6  Final conclusions and future work 
 
W. chondrophila has been utilised as a comparative model organism for the study of 
Chlamydia infection (Fehr et al., 2016). However, its faster life cycle and its broad range 
of hosts as well as its higher virulence has highlighted differences from other organisms 
in the same class that would argue against its use as a model. Within this body of work, 
our data supports the concept that W. chondrophila holds very pronounced differences 
with C. trachomatis in the context of the host innate immune response. Our comparative 
studies with C. trachomatis L2 have indicated that its potential as a Chlamydia infection 
model is limited and that additional considerations must be made in future comparative 
studies.  
 
Our data show that cathelicidins can interact with W. chondrophila and C. trachomatis in 
distinct ways. With C. trachomatis L2, we observed the classical and extensively 
described antimicrobial properties of cathelicidins against this pathogen, affirming that a 
therapeutic potential exists for cathelicidins to treat C. trachomatis. However, a 
significant body of work remains to be undertaken, regarding other chlamydial species 
and in vivo models of infection. 
 
 A limitation of the technique used to monitor bacterial replication (quantitative PCR) is 
that both the DNA of dead and viable bacteria is quantified. Future work would involve 
the use of more specific techniques, such as the Viability PCR, that could differentiate 
and quantify viable bacteria, the ones that would have the ability to infect after the 
treatments. 
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The novel results obtained with W. chondrophila point to an altered susceptibility to 
cathelicidin treatment and indeed, a specific interaction with these peptides. We observed 
that this pathogen may possess new mechanisms of resistance to these peptides and thus 
more work needs to be performed to clarify the nature of this interaction. In the context 
of inflammatory modulation by cathelicidins in Waddlia and Chlamydia infection, we did 
not observe differential effects when comparing the two pathogens. However, we propose 
that to fully understand the potential of these peptides in modulating the inflammatory 
response, it will be necessary to study other key cytokines involved in the host response 
to chlamydial infection.  Our work proves that although the two pathogens share a similar 
infection biology, they possess very different susceptibilities to cathelicidin treatments. 
Thus, a further investigation of these differences will not only provide a greater 
understanding of the underlying mechanisms of infection of these organisms, but inform 
the discovery and development of new treatments.  
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5  Results appendix  
 
 
5.1   The effect of cathelicidins on IL-8 production in C. trachomatis infection 
 
 
5.1.1 Direct cathelicidin treatment of C. trachomatis MOI 0.1 
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Figure 29. IL-8 release (pg/ml) after C. trachomatis exposure to cathelicidins. C. trachomatis 
MOI 0.1 was exposed for 1 hour to different cathelicidin concentrations prior host cell infection 
for a further 1 hour. After 24 hours and 48 hours incubation, supernatants were collected and 
analysed by ELISA using uninfected cells as control. Results are shown as a mean ± SEM of three 
independent experiments. Statistical analysis was performed by one-way ANOVA with Dunnett’s 
post-hoc test to compare each treatment to the untreated infected control (0µg/ml). *p£0.05, ** 
p£0.01.  
 
 
5.1.2   Host cell exposure to cathelicidins prior to C. trachomatis infection MOI 0.1 
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Figure 30. IL-8 release (pg/ml) after host cell exposure to cathelicidins prior to infection 
(MOI 0.1). HEp2 cells were pre-incubated for 1 hour with various cathelicidin concentrations 
and then infected for a further 1 hour with C. trachomatis (MOI 0.1). After 24 hours incubation, 
supernatants were collected and analysed using uninfected cells as control. Results are shown as 
a mean ± SEM of three independent experiments. Statistical analysis was performed by one-way 
ANOVA with Dunnett’s post-hoc test to compare each treatment to the infected control (0µg/ml).  
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